Publications from OUS - Clinical Addiction Research

349 publications found

Publications 2025

1. Andersen KAA, Holmøy B, Kvam TM, Johnson MW (2025)
   Adverse reactions among psychedelic users: Norwegian validation of the Challenging Experience Questionnaire
   J Psychiatr Res, 189, 18-25
   DOI 10.1016/j.jpsychires.2025.05.062, PubMed 40466556
2. Auestad N, Bogstrand ST, Vallersnes OM, Lerdal A, Wüsthoff LEC (2025)
   Cognitive Function among People with Severe Substance Use
   Eur Addict Res, 31 (2), 133-144
   DOI 10.1159/000543755, PubMed 39900001
3. Batalla A, Bramness JG (2025)
   Integrating substance-induced psychosis (SIP) into the positive and negative symptoms disorder (PND) spectrum
   Eur Arch Psychiatry Clin Neurosci (in press)
   DOI 10.1007/s00406-025-02104-x, PubMed 40938402
4. Bramness JG (2025)
   Naltrekson i behandlingen av alkoholavhengighet
   Tidsskr Nor Laegeforen, 145 (13)
   DOI 10.4045/tidsskr.25.0514, PubMed 41196211
5. Bramness JG, Bretteville-Jensen AL, Bachs L, Vevelstad MS (2025)
   Semisyntetiske cannabinoider – bort i hampen?
   Tidsskr Nor Laegeforen, 145 (3)
   DOI 10.4045/tidsskr.24.0663, PubMed 40042022
6. Bramness JG, Hjellvik V, Nystad W, Høye A, Lid TG (2025)
   Responses to the AUDIT questionnaire in the population-based Tromsø surveys as predictor of a diagnosis of alcohol use disorder in Norwegian central health registries-an NCDNOR study
   Eur J Public Health (in press)
   DOI 10.1093/eurpub/ckaf131, PubMed 41071593
7. Bramness JG, Lid TG, Bolstad I, Lien L, Abebe DS (2025)
   Predictors of alcohol use disorder in patients with hypertension: a national registry-based cohort study
   BMC Public Health, 25 (1), 2352
   DOI 10.1186/s12889-025-23579-2, PubMed 40610983
8. Bramness JG, Mørland J, Moe J, Pandey S, Skulberg KR, Bolstad I (2025)
   The level of response to alcohol is related to level of se-phosphate in the general population
   Alcohol Alcohol, 60 (6)
   DOI 10.1093/alcalc/agaf065, PubMed 41165320
9. Bramness JG, Rognli EB, Høye A, Heiberg IH (2025)
   Alcohol-induced psychosis and delirium tremens: a comparison with alcohol dependence on demographic characteristics, mortality, and morbidity
   BMC Psychiatry, 25 (1), 285
   DOI 10.1186/s12888-025-06753-z, PubMed 40133875
10. Finstad J, Clausen T, Røise O, Rosseland LA, Havnes IA (2025)
    Challenges in pain management and opioid prescribing practices following traumatic injury: a focus group study with orthopedic surgeons and general practitioners
    Scand J Prim Health Care, 43 (4), 864-879
    DOI 10.1080/02813432.2025.2517769, PubMed 40509554
11. Grzych G, Lee GR, Alpdemir M, Gernez E, Anseeuw K, Bjorke-Monsen AL, Croes K, El-Khoury JM, Hamzic J, Noyce AJ, Stankovic S, Rolland B, Bramness J, Vermeersch P, Cavalier E (2025)
    Addressing the silent epidemic of recreational nitrous oxide use: a position, call to action and recommendations by the European Federation of Clinical Chemistry and Laboratory Medicine Committee on Biological Markers of Nitrous Oxide Abuse
    Clin Chem Lab Med (in press)
    DOI 10.1515/cclm-2025-1060, PubMed 41292176
12. Grønnerød C, Rønningen T, Haugsjå IR, Andersen KAA, Lindvall Dahlgren C, Kvam TM (2025)
    Recreational MDMA use in Norway: results from an internet convenience sample
    Front Psychiatry, 16, 1619676
    DOI 10.3389/fpsyt.2025.1619676, PubMed 41080781
13. Heiberg IH, Balteskard L, Jacobsen BK, Bramness JG, Nesvåg R, Tveit KM, Høye A (2025)
    Inclusion in the cancer patient pathway among cancer patients with and without pre-existing mental or substance use disorders: a nationwide register-based study
    BMC Public Health, 25 (1), 1991
    DOI 10.1186/s12889-025-23180-7, PubMed 40442606
14. Høiland K, Arnevik EKA, Diep LM, Mathisen T, Nielsen AS, Egeland J (2025)
    Predictors of high- and low-risk drinking after group treatment for alcohol use disorder
    BJPsych Open, 11 (4), e150
    DOI 10.1192/bjo.2025.10047, PubMed 40653622
15. Høiland K, Arnevik EKA, Diep LM, Mathisen T, Witkiewitz K, Egeland J (2025)
    Keep on Keeping on? Patient Factors Predicting Discontinuation in Alcohol Use Disorder Treatment
    Subst Use Misuse, 60 (12), 1808-1819
    DOI 10.1080/10826084.2025.2519404, PubMed 40555227
16. Høiland K, Arnevik EKA, Nielsen AS, Egeland J (2025)
    Gender differences in alcohol use disorder treatment: sociodemographic, mental health, personality, and neuropsychological factors
    Nord J Psychiatry, 79 (5), 387-396
    DOI 10.1080/08039488.2025.2508415, PubMed 40432485
17. Kaldenbach S, Leonhardt M, Strand TA, Holten-Andersen M (2025)
    Mental health and energy drink consumption among Norwegian adolescents; a cross-sectional study
    BMC Public Health, 25 (1), 2158
    DOI 10.1186/s12889-025-23432-6, PubMed 40495156
18. Kerr-Little A, Bramness JG, Newberry RC, Biong S (2025)
    Dog ownership for people with substance use disorder: self-reported influence on substance use and mental health
    Subst Abuse Treat Prev Policy, 20 (1), 27
    DOI 10.1186/s13011-025-00653-x, PubMed 40537824
19. Kleppang AL, Hagquist C, Stea TH, Leonhardt M, Bonsaksen T, Lien L, Steigen AM (2025)
    Social media use, gaming and quality of life among adolescents in Norway: results from the Young-HUNT study
    Health Qual Life Outcomes, 23 (1), 113
    DOI 10.1186/s12955-025-02428-1, PubMed 41174604
20. Kvarstein EH, Bremer K, Baltzersen ÅL, Ekberg A, Normann-Eide E, Ulvestad DA, Pedersen G, Wilberg T (2025)
    Sustainability of Mentalization-Based Treatment Programs for Poorly Functioning Patients With Borderline Personality Disorder. Can We Really Keep It Up?
    Personal Ment Health, 19 (4), e70036
    DOI 10.1002/pmh.70036, PubMed 40831379
21. Lie AK, Lichtwarck H, Raveen RR, Sjåfjell T, Wüsthoff L, Havnes IA (2025)
    The individual care plan as a learning tool
    Tidsskr Nor Laegeforen, 145 (9)
    DOI 10.4045/tidsskr.25.0396, PubMed 40878572
22. Lund O, Raudeberg R, Johansen H, Myhre ML, Walderhaug E, Poreh A, Egeland J (2025)
    Factor Structure of the Conners Continuous Performance Test Third Edition (CCPT-3): Exploratory Factor Analysis in a Mixed Clinical Sample
    J Atten Disord, 29 (13), 1163-1176
    DOI 10.1177/10870547251341928, PubMed 40535991
23. Moe JS, Bramness JG, Bolstad I, Mørland JG, Gorwood P, Ramoz N (2025)
    Association Between GABRG2 and Self-Rating of the Effects of Alcohol in a French Young Adult Sample
    Risk Manag Healthc Policy, 18, 291-304
    DOI 10.2147/RMHP.S483830, PubMed 39882063
24. Mordal J, Juya F, Holtan L, Vederhus JK, Opheim A, Brenna IH, Enger AE, Weimand B, Solli KK, Tanum L (2025)
    High induction rate onto extended-release naltrexone for people with opioid use disorder: experiences from a Norwegian naturalistic study
    Addict Sci Clin Pract, 20 (1), 50
    DOI 10.1186/s13722-025-00576-9, PubMed 40524244
25. Myhre MØ, Walby FA, Klungsøyr O, Bramness JG, Mehlum L (2025)
    Factors associated with self-harm in patients with substance use disorders who died by suicide: national hybrid questionnaire registry study
    Br J Psychiatry, 1-7 (in press)
    DOI 10.1192/bjp.2025.22, PubMed 40143678
26. Myklebust LHR, Eide D, Wüsthoff LEC, Melis F, Oldervoll AL, De Pirro S, Clausen T (2025)
    Changes in Self-Reported Mental Health, Anxiety, and Depression among Patients in Heroin-Assisted Treatment: Findings from a Norwegian Trial Project
    Eur Addict Res, 31 (4), 286-296
    DOI 10.1159/000547375, PubMed 40695250
27. Nygård-Odeh K, Soløy-Nilsen H, Gangsøy-Kristiansen M, Brekke OL, Mollnes TE, Berk M, Bramness JG (2025)
    Hostility is Associated with Interferon γ Inducible Protein 10 in Opioid Maintenance Treatment Patients with Chronic Hepatitis C
    Clin Psychopharmacol Neurosci, 23 (3), 488-493
    DOI 10.9758/cpn.24.1262, PubMed 40660694
28. Opheim E, Malme K, Dalgard O, Sørli H, Backe Ø, Foshaug T, Dahl V, Stålberg K, Harestad B, Gjøstein RK, Indreiten MT, Rykkvin R, Ulstein K, Steen TW, Wüsthoff L, Midgard H (2025)
    Changes in Risk Behaviour Among People With Recent Injecting Drug Use in Oslo 2002-2024
    Drug Alcohol Rev, 45 (1), e70060
    DOI 10.1111/dar.70060, PubMed 41139587
29. Redondo CL, Weimand B, Benth JŠ, Vederhus JK, Mordal J, Enger A, Tanum L, Solli KK (2025)
    Changes in quality of life during 52 weeks of extended-release naltrexone treatment, subsequent by a 1-year post-treatment period
    Drug Alcohol Depend, 276, 112917 (in press)
    DOI 10.1016/j.drugalcdep.2025.112917, PubMed 41100958
30. Rognli EB, Andersen KAA, Aas EM, Reme SE, Lystad JU, Stavseth MR, Arnevik EA (2025)
    The effectiveness of Individual Placement and Support on vocational outcomes for patients with substance use disorders: A pragmatic superiority randomized controlled trial of Individual Placement and Support versus enhanced self-help
    Addiction, 120 (12), 2547-2558
    DOI 10.1111/add.70155, PubMed 40702951
31. Romm KL, Skoge M, Barrett EA, Berentzen LC, Bergsager D, Fugelli P, Bjella T, Gardsjord ES, Kling K, Kruse SH, Kværner KJ, Melle I, Mork E, Ihler HM, Rognli EB, Simonsen C, Værnes TG, Aminoff SR (2025)
    A Mobile Health Intervention to Support Collaborative Decision-Making in Mental Health Care: Development and Usability
    JMIR Form Res, 9, e57614
    DOI 10.2196/57614, PubMed 39823632
32. Sayar H, Wilberg T, Eikenæs IU, Ekberg A, Leitemo K, Morken KTE, Oftedal E, Omvik S, Ulvestad DA, Pedersen G, Kvarstein EH (2025)
    Improvement of alexithymia in patients treated in mental health services for personality disorders: a longitudinal, observational study
    Front Psychiatry, 16, 1558654
    DOI 10.3389/fpsyt.2025.1558654, PubMed 40206651
33. Scarth M, Havnes IA, Bjørnebekk A (2025)
    Anabolic-androgenic steroid use disorder: case for recognition as a substance use disorder with specific diagnostic criteria
    Br J Psychiatry, 1-5 (in press)
    DOI 10.1192/bjp.2025.73, PubMed 40355134
34. Scarth M, Havnes IA, Jørstad ML, Bjørnebekk A (2025)
    Psychological traits associated with anabolic androgenic steroid use and dependence: an exploratory cross-sectional study among female athletes
    BMC Womens Health, 25 (1), 214
    DOI 10.1186/s12905-025-03711-5, PubMed 40325431
35. Skoge M, Aminoff SR, Barrett EA, Bryhni GE, Kling K, Kværner KJ, Melle I, Mork E, Simonsen C, Støme LN, Vink J, Værnes TG, Romm KL (2025)
    A Mobile App Designed to Promote Shared Decision-Making in the Treatment of Psychotic Disorders: Feasibility and Acceptability Study
    JMIR Hum Factors, 12, e68813
    DOI 10.2196/68813, PubMed 40644621
36. Støme LN (2025)
    Defining early health technology assessment: building consensus using Delphi technique: a commentary on implementation and diffusion of early HTA
    Int J Technol Assess Health Care, 41 (1), e32
    DOI 10.1017/S0266462325100214, PubMed 40461436
37. Svendsen V, Stavseth MR, Skardhamar T, Havnes IA, Bukten A (2025)
    Substance use disorders, severe mental illness and risk of reoffending among women released from prison: a national cohort study
    Sci Rep, 15 (1), 15473
    DOI 10.1038/s41598-025-00215-y, PubMed 40316570
38. Todd-Kvam J, Johnsen B, Appleton C, Stavseth MR, Dahl H, Bukten A (2025)
    Prevalence and patterns of mental health disorders in long-term preventive detention: a 13-year national cohort study
    BMC Psychiatry, 25 (1), 879
    DOI 10.1186/s12888-025-07357-3, PubMed 41023927
39. Tungesvik HM, Padrela B, Groote I, Bjørnerud A, Geier OM, Hisdal J, Mutsaerts HJ, Bjørnebekk A (2025)
    Imaging cerebral circulation in long-term anabolic-androgenic steroid users and non-using weightlifters
    Drug Alcohol Depend, 275, 112829
    DOI 10.1016/j.drugalcdep.2025.112829, PubMed 40865192
40. Tunstad PA, Kvam TM, Uthaug MV, Stewart LH, Andersen KAA, Grønnerød C (2025)
    Contextual and experiential aspects of the psychedelic experience predicting improvement in subjective wellbeing: results from a Norwegian internet convenience sample
    Front Pharmacol, 16, 1556299
    DOI 10.3389/fphar.2025.1556299, PubMed 40276609
41. Tverborgvik T, Stavseth MR, Lokdam NT, Jordan A, Bukten A (2025)
    The burden of mental health and somatic disorders among people experiencing incarceration later in life: A 13-year cohort study
    Soc Sci Med, 373, 118007
    DOI 10.1016/j.socscimed.2025.118007, PubMed 40158450
42. Ørjasæter NO, Kværner KJ, Støme LN (2025)
    Value-Based Framework for Evaluating Pre-Commercial Procurement: Case Study of Value-Based Key Performance Indicators
    JMIR Form Res, 9, e71279
    DOI 10.2196/71279, PubMed 40811851
43. Aasen J, Nilsson F, Sørensen T, Leonhardt M (2025)
    Promoting Sustained Real-Life Benefits of Virtual Reality-Based Interventions in People With Mental Health and Substance Use Disorders: Qualitative Study
    JMIR Form Res, 9, e57643
    DOI 10.2196/57643, PubMed 40835410

Publications 2024

1. Abdullah R, Bjørnebekk A, Hauger LE, Hullstein IR, Edvardsen T, Haugaa KH, Almaas VM (2024)
   Severe biventricular cardiomyopathy in both current and former long-term users of anabolic-androgenic steroids
   Eur J Prev Cardiol, 31 (5), 599-608
   DOI 10.1093/eurjpc/zwad362, PubMed 37992194
2. Almaas VM, Abdullah R, Edvardsen T, Haugaa KH, Bjørnebekk A (2024)
   Comment on 'Anabolic-androgenic steroids and cardiac function'
   Eur J Prev Cardiol, 31 (13), e97-e98
   DOI 10.1093/eurjpc/zwae183, PubMed 38788779
3. Bramness JG, Edland-Gryt M (2024)
   Rettelse: Økende bruk av kokain
   Tidsskr Nor Laegeforen, 144
   DOI 10.4045/tidsskr.24.0247, PubMed 38738574
4. Bramness JG, Hjellvik V, Høye A, Tesli M, Haram M, Nystad W, Krokstad S (2024)
   The epidemiology of major depression among adults in Norway: an observational study on the concurrence between population surveys and registry data - a NCDNOR project
   BMC Public Health, 24 (1), 1330
   DOI 10.1186/s12889-024-18754-w, PubMed 38755615
5. Bramness JG, Hjorthøj C, Niemelä S, Taipale H, Rognli EB (2024)
   Discussing the concept of substance-induced psychosis (SIP)
   Psychol Med, 54 (11), 2852-2856
   DOI 10.1017/S0033291724001442, PubMed 39252388
6. Bramness JG, Hjorthøj C, Niemelä S, Taipale H, Rognli EB (2024)
   Problematic diagnosis of substance-induced disorders in ICD-11
   Eur Psychiatry, 67 (1), e51
   DOI 10.1192/j.eurpsy.2024.1763, PubMed 39291557
7. Bukten A, Stavseth MR (2024)
   Estimated effects of opioid agonist treatment in prison on all-cause mortality and overdose mortality in people released from prison in Norway: a prospective analysis of data from the Norwegian Prison Release Study (nPRIS)
   Lancet Public Health, 9 (7), e421-e431
   DOI 10.1016/S2468-2667(24)00098-7, PubMed 38942554
8. Bukten A, Virtanen S, Hesse M, Chang Z, Kvamme TL, Thylstrup B, Tverborgvik T, Skjærvø I, Stavseth MR (2024)
   The prevalence and comorbidity of mental health and substance use disorders in Scandinavian prisons 2010-2019: a multi-national register study
   BMC Psychiatry, 24 (1), 95
   DOI 10.1186/s12888-024-05540-6, PubMed 38317111
9. Bukten A, Virtanen S, Hesse M, Thylstrup B, Kvamme TL, Seid AK, Chang Z, Skjærvø I, Tverborgvik T, Stavseth MR (2024)
   The prevalence of substance use disorders among people in Norwegian, Danish and Swedish prisons: A multi-national cohort study, 2010-19
   Addiction, 119 (7), 1264-1275
   DOI 10.1111/add.16477, PubMed 38529890
10. Ellefsen R, De Pirro S, Haukland V, Wüsthoff LEC, Arnevik EA (2024)
    "It's a delicate balance": clinicians' experiences of providing heroin-assisted treatment
    Harm Reduct J, 21 (1), 230
    DOI 10.1186/s12954-024-01135-2, PubMed 39741328
11. Finstad J, Røise O, Clausen T, Rosseland LA, Havnes IA (2024)
    A qualitative longitudinal study of traumatic orthopaedic injury survivors' experiences with pain and the long-term recovery trajectory
    BMJ Open, 14 (1), e079161
    DOI 10.1136/bmjopen-2023-079161, PubMed 38191252
12. Gainullin M, Federico L, Røkke Osen J, Chaban V, Kared H, Alirezaylavasani A, Lund-Johansen F, Wildendahl G, Jacobsen JA, Sarwar Anjum H, Stratford R, Tennøe S, Malone B, Clancy T, Vaage JT, Henriksen K, Wüsthoff L, Munthe LA (2024)
    People who use drugs show no increase in pre-existing T-cell cross-reactivity toward SARS-CoV-2 but develop a normal polyfunctional T-cell response after standard mRNA vaccination
    Front Immunol, 14, 1235210
    DOI 10.3389/fimmu.2023.1235210, PubMed 38299149
13. Gregersen I, Scarth ME, Abdullah R, Thorsby PM, Hauger LE, Haugaa KH, Sagen EL, Michelsen AE, Ueland T, Edvardsen T, Aukrust P, Almaas VM, Bjørnebekk AK, Halvorsen B (2024)
    Elevated interleukin 8 and matrix metalloproteinase 9 levels are associated with myocardial pathology in users of anabolic-androgenic steroids
    Eur J Prev Cardiol, 31 (12), 1469-1476
    DOI 10.1093/eurjpc/zwae126, PubMed 38573232
14. Havig SM, Berg-Pedersen RM, Krabseth HM, Müller LD, Haugaa K, Zare HK, Gjesdal K, Krajci P, Opdal MS (2024)
    Effect on QTc interval by switching from methadone to equipotent R-methadone dose in methadone maintenance treatment patients
    Basic Clin Pharmacol Toxicol, 134 (4), 519-530
    DOI 10.1111/bcpt.13982, PubMed 38308508
15. Havnes IA, Henriksen HCB, Johansen PW, Bjørnebekk A, Neupane SP, Hisdal J, Seljeflot I, Wisløff C, Jørstad ML, McVeigh J, Jørgensen AP (2024)
    Off-label use of clomiphene citrate to treat anabolic androgenic steroid induced hypogonadism upon cessation among men (CloTASH) - A pilot study protocol
    MethodsX, 13, 102810
    DOI 10.1016/j.mex.2024.102810, PubMed 39022178
16. Henriksen HCB, Havnes IA, Jørstad ML, Abdullah R, Thorsby PM, Hauger LE, Edvardsen T, Haugaa KH, Almaas VM, Bjørnebekk A (2024)
    Treatment-seeking behavior and cardiovascular morbidity among men with anabolic-androgenic steroid use: A cross-sectional study
    Scand J Med Sci Sports, 34 (1), e14554
    DOI 10.1111/sms.14554, PubMed 38268076
17. Høiland K, Arnevik EA, Egeland J (2024)
    Alcohol use disorder and fitness to drive: Discrepancies between health professionals’ evaluations and objective measures of alcohol use and cognitive functioning
    Nordic Studies on Alcohol and Drugs, 0, 1-13
    DOI 10.1177/1455072523121997, PublikaID 481
18. Høiland K, Arnevik EKA, Diep LM, Mathisen T, Witkiewitz K, Egeland J (2024)
    Impaired or not impaired: The accuracy of the Montreal Cognitive Assessment in detecting cognitive impairment among patients with alcohol use disorder
    Alcohol Clin Exp Res (Hoboken), 48 (11), 2070-2078
    DOI 10.1111/acer.15437, PubMed 39245727
19. Høiland K, Arnevik EKA, Egeland J (2024)
    Alcohol use disorder and fitness to drive: Discrepancies between health professionals' evaluations and objective measures of alcohol use and cognitive functioning
    Nordisk Alkohol Nark, 41 (4), 426-438
    DOI 10.1177/14550725231219972, PubMed 39309203
20. Johannessen DA, Overå S, Arnevik EA (2024)
    The role of contextual factors in avenues to recover from gambling disorder: a scoping review
    Front Psychol, 15, 1247152
    DOI 10.3389/fpsyg.2024.1247152, PubMed 38410405
21. Klonteig S, Scarth M, Bjørnebekk A (2024)
    Sleep pathology and use of anabolic androgen steroids among male weightlifters in Norway
    BMC Psychiatry, 24 (1), 62
    DOI 10.1186/s12888-024-05516-6, PubMed 38254047
22. Kyrkjebø-Urheim T, Andersen CD, Ellefsen R (2024)
    Pasienters opplevelse av livskvalitet i heroinassistert behandling
    Sykepleien Forskning, 19(97141), e-97141
    DOI 10.4220/Sykepleienf.2024.97141, PublikaID 510
23. Leonhardt M, Bramness JG, Rognli EB, Lien L (2024)
    Frequency and patterns of substance-induced psychosis in persons with concurrent mental health and substance use disorders during the COVID-19 pandemic: A Norwegian register-based cohort study
    Eur Psychiatry, 67 (1), e82
    DOI 10.1192/j.eurpsy.2024.1797, PubMed 39676544
24. Lokdam NT, Stavseth MR, Skjaervø I, Bukten A (2024)
    Treatment utilization among people with drug use disorders in prison: a national longitudinal cohort study
    Health Justice, 12 (1), 46
    DOI 10.1186/s40352-024-00302-8, PubMed 39589678
25. Melis F, Clausen T, Castel C, Dadras O, De Pirro S, Myklebust LH, Oldervoll A, Wüsthoff LE, Eide D (2024)
    Patient Characteristics From Norway's First Heroin-Assisted Treatment Clinics
    Subst Use Addctn J, 46 (1), 13-24
    DOI 10.1177/29767342241271991, PubMed 39308161
26. Myhre MØ, Rognli EB, Walby FA, Bramness JG, Mehlum L (2024)
    The annual trend of suicide rates from 2010 to 2021 in patients with cannabis use disorder - a national registry study
    Soc Psychiatry Psychiatr Epidemiol, 60 (7), 1603-1611
    DOI 10.1007/s00127-024-02781-4, PubMed 39466446
27. Myklebust LH, Eide D, Arnevik EA, Dadras O, De Pirro S, Ellefsen R, Fadnes LT, Hesse M, Kvamme TL, Melis F, Oldervoll A, Thylstrup B, Wusthoff LEC, Clausen T (2024)
    Evaluation of heroin-assisted treatment in Norway: protocol for a mixed methods study
    BMC Health Serv Res, 24 (1), 398
    DOI 10.1186/s12913-024-10767-w, PubMed 38553691
28. Piatkowski T, Havnes IA, Kill E, Barratt MJ (2024)
    "The compounds for females are really commonly faked!": Women's challenges in anabolic steroid acquisition and the place of drug checking interventions
    Drug Alcohol Rev, 43 (7), 1962-1966
    DOI 10.1111/dar.13931, PubMed 39187954
29. Rodríguez-Cano R, Lotre K, von Soest T, Rognli EB, Bramness JG (2024)
    Loneliness in adolescence and prescription of psychotropic drugs in adulthood: 23-year longitudinal population-based and registry study
    BJPsych Open, 10 (2), e61
    DOI 10.1192/bjo.2024.22, PubMed 38465662
30. Rognli EB, Bukten A, Bramness JG, Stavseth MR (2024)
    Tidligere kriminalitet og psykisk helsehjelp hos personer med soningserfaring som blir dømt til tvungent psykisk helsevern
    Tidsskr Nor Laegeforen, 144 (9)
    DOI 10.4045/tidsskr.23.0850, PubMed 39166997
31. Rognli EB, Høye A, Bramness JG (2024)
    Methamphetamine-Induced Psychosis and Schizophrenia: A Call for Special Attention: Response to Zhu et al
    Am J Psychiatry, 181 (2), 168-169
    DOI 10.1176/appi.ajp.20230522, PubMed 38298080
32. Skjærvø I, Stavseth MR, Friestad C, Skardhamar T, Tverborgvik T, Bukten A (2024)
    Characteristics and risk of reimprisonment among children and young adults in Norwegian prisons. A 20-year cohort stud
    Journal of Criminal Justice, 93 (102219), 1-9
    DOI 10.1016/j.jcrimjus.2024.102219, PublikaID 531
33. Svendsen VG, Bukten A, Skardhamar T, Stavseth MR (2024)
    Mortality in women with a history of incarceration in Norway: a 20-year national cohort study
    Int J Epidemiol, 53 (2)
    DOI 10.1093/ije/dyae032, PubMed 38481122
34. Tjelta T, Bogstrand ST, Lerdal A, Wüsthoff LEC, Edvardsen HME, Johannessen A (2024)
    Screening and Following Up Harmful Alcohol Use "… is Not Necessarily Your Primary Focus": A Qualitative Study Exploring Health Professionals' Experiences Addressing Harmful Alcohol Use in a Norwegian Hospital
    J Multidiscip Healthc, 17, 5189-5198
    DOI 10.2147/JMDH.S475750, PubMed 39558926
35. Tungesvik HM, Bjørnebekk A, Hisdal J (2024)
    Impaired vascular function among young users of anabolic-androgenic steroids
    Sci Rep, 14 (1), 19201
    DOI 10.1038/s41598-024-70110-5, PubMed 39160232
36. Wüsthoff LEC, Lund-Johansen F, Henriksen K, Wildendahl G, Jacobsen JA, Gomes L, Anjum HS, Barlinn R, Kran AB, Munthe LA, Vaage JT (2024)
    Seroprevalence of SARS-CoV-2 and humoral immune responses to COVID-19 mRNA vaccines among people who use drugs - in the light of tailored mitigating strategies
    Harm Reduct J, 21 (1), 120
    DOI 10.1186/s12954-024-01023-9, PubMed 38890611

Publications 2023

1. Andersen SN, Hyatt JM, Lobmaier P, Stavseth MR, Bukten A (2023)
   Leaving Their Drugs at the Gate? Exploring Changes in Drug Use From Before to During Incarceration in Norway
   Int J Offender Ther Comp Criminol, 69 (9), 1207-1229
   DOI 10.1177/0306624X231168596, PubMed 37312513
2. Bramness JG, Edland-Gryt M (2023)
   [Growth in use of cocaine]
   Tidsskr Nor Laegeforen, 143 (1)
   DOI 10.4045/tidsskr.23.0680, PubMed 38258712
3. Bramness JG, Syse A, Rognli EB (2023)
   [Substance-induced psychosis – a problematic diagnosis]
   Tidsskr Nor Laegeforen, 143 (3)
   DOI 10.4045/tidsskr.22.0762, PubMed 36811432
4. Bukten A, Skjærvø I, Stavseth MR (2023)
   Exploring mental health comorbidities and opioid agonist treatment coverage among people in prison: A national cohort study 2010-2019
   Drug Alcohol Depend, 250, 110896
   DOI 10.1016/j.drugalcdep.2023.110896, PubMed 37515826
5. Ellefsen R (2023)
   Narkotikapolitikk i endring: Heroinklinikkenes oppkomst i Norge
   Nordisk Alkohol Nark, 41 (3), 307-325
   DOI 10.1177/14550725231207251, PubMed 38903889
6. Ellefsen R, Wüsthoff LEC, Arnevik EA (2023)
   Patients' satisfaction with heroin-assisted treatment: a qualitative study
   Harm Reduct J, 20 (1), 73
   DOI 10.1186/s12954-023-00808-8, PubMed 37312181
7. Ellingsen MM, Clausen T, Johannesen SL, Martinsen EW, Hallgren M (2023)
   Effects of Acute Exercise on Affect, Anxiety, and Self-Esteem in Poly-Substance Dependent Inpatients
   Eur Addict Res, 29 (4), 285-293
   DOI 10.1159/000531042, PubMed 37393901
8. Henriksen HCB, Havnes IA, Jørstad ML, Bjørnebekk A (2023)
   Health service engagement, side effects and concerns among men with anabolic-androgenic steroid use: a cross-sectional Norwegian study
   Subst Abuse Treat Prev Policy, 18 (1), 19
   DOI 10.1186/s13011-023-00528-z, PubMed 37013635
9. Jamt REG, Bukten A, Stavseth MR, Bogstrand ST, Tverborgvik T (2023)
   All-cause and cause-specific mortality among individuals imprisoned for driving under the influence of alcohol and drugs in Norway (2000-2016): a retrospective cohort study
   BMJ Open, 13 (12), e078848
   DOI 10.1136/bmjopen-2023-078848, PubMed 38159948
10. Jørstad ML, Scarth M, Torgersen S, Pope HG, Bjørnebekk A (2023)
    Clustering psychopathology in male anabolic-androgenic steroid users and nonusing weightlifters
    Brain Behav, 13 (7), e3040
    DOI 10.1002/brb3.3040, PubMed 37150843
11. Malme KB, Ulstein K, Finbråten AK, Wüsthoff LEC, Kielland KB, Hauge J, Dalgard O, Midgard H (2023)
    Hepatitis C treatment uptake among people who inject drugs in Oslo, Norway: A registry-based study
    Int J Drug Policy, 116, 104044
    DOI 10.1016/j.drugpo.2023.104044, PubMed 37149914
12. Næss O, Ekeland TJ, Arnevik EA, Aarstad J, Lid TG (2023)
    Governing by commissioning services - Implementing alcohol screening and brief interventions in hospital settings in Norway
    Eval Program Plann, 98, 102271
    DOI 10.1016/j.evalprogplan.2023.102271, PubMed 36921405
13. Opheim E, Dalgard O, Ulstein K, Sørli H, Backe Ø, Foshaug T, Couëssurel Wüsthoff LE, Midgard H (2023)
    Towards elimination of hepatitis C in Oslo: Cross-sectional prevalence studies among people who inject drugs
    Int J Drug Policy, 123, 104279
    DOI 10.1016/j.drugpo.2023.104279, PubMed 38061225
14. Rognli EB, Dalsrud MK, Wüsthoff LEC, Arnevik EA (2023)
    [Poor uptake of service provision at a drug-related emergency department – a qualitative study]
    Tidsskr Nor Laegeforen, 143 (5)
    DOI 10.4045/tidsskr.22.0471, PubMed 36987889
15. Rognli EB, Heiberg IH, Jacobsen BK, Høye A, Bramness JG (2023)
    Transition From Substance-Induced Psychosis to Schizophrenia Spectrum Disorder or Bipolar Disorder
    Am J Psychiatry, 180 (6), 437-444
    DOI 10.1176/appi.ajp.22010076, PubMed 37132221
16. Scarth M, Hauger LE, Thorsby PM, Leknes S, Hullstein IR, Westlye LT, Bjørnebekk A (2023)
    Supraphysiological testosterone levels from anabolic steroid use and reduced sensitivity to negative facial expressions in men
    Psychopharmacology (Berl), 241 (4), 701-715
    DOI 10.1007/s00213-023-06497-2, PubMed 37993638
17. Scarth M, Westlye LT, Havnes IA, Bjørnebekk A (2023)
    Investigating anabolic-androgenic steroid dependence and muscle dysmorphia with network analysis among male weightlifters
    BMC Psychiatry, 23 (1), 342
    DOI 10.1186/s12888-023-04781-1, PubMed 37193971
18. Skauen JE, Pallesen S, Bjørnebekk A, Chegeni R, Syvertsen A, Petróczi A, Sagoe D (2023)
    Prevalence and correlates of androgen dependence: a meta-analysis, meta-regression analysis and qualitative synthesis
    Curr Opin Endocrinol Diabetes Obes, 30 (6), 309-323
    DOI 10.1097/MED.0000000000000822, PubMed 37410490
19. Stavseth MR (2023)
    [Remember to clean the data before use!]
    Tidsskr Nor Laegeforen, 143 (2)
    DOI 10.4045/tidsskr.22.0825, PubMed 36718890
20. Svendsen VG, Stavseth MR, Skardhamar T, Bukten A (2023)
    Psychiatric morbidity among women in Norwegian prisons, 2010-2019: a register-based study
    BMC Psychiatry, 23 (1), 390
    DOI 10.1186/s12888-023-04886-7, PubMed 37268924
21. Tverborgvik T, Stavseth MR, Bukten A (2023)
    The association between drug use and mortality in a norwegian prison cohort: a prospective cohort study
    Health Justice, 11 (1), 22
    DOI 10.1186/s40352-023-00223-y, PubMed 37058181

Publications 2022

1. Bjørnebekk A, Scarth M, Neupane SP, Westlye LT, Hullstein IR, Thorsby PM, Halvorsen B (2022)
   Use of High-Dose Androgens Is Associated with Reduced Brain-Derived Neurotrophic Factor in Male Weightlifters
   Neuroendocrinology, 113 (1), 36-47
   DOI 10.1159/000526418, PubMed 35944495
2. Bolstad I, Alakokkare AE, Bramness JG, Rognli EB, Levola J, Mustonen A, Miettunen J, Niemelä S (2022)
   The relationships between use of alcohol, tobacco and coffee in adolescence and mood disorders in adulthood
   Acta Psychiatr Scand, 146 (6), 594-603
   DOI 10.1111/acps.13506, PubMed 36177725
3. Bramness JG (2022)
   [Antidepressants are not addictive]
   Tidsskr Nor Laegeforen, 142 (13)
   DOI 10.4045/tidsskr.22.0562, PubMed 36164795
4. Bukten A, Lokdam NT, Skjærvø I, Ugelvik T, Skurtveit S, Gabrhelík R, Skardhamar T, Lund IO, Havnes IA, Rognli EB, Chang Z, Fazel S, Friestad C, Hesse M, Lothe J, Ploeg G, Dirkzwager AJE, Clausen T, Tjagvad C, Stavseth MR (2022)
   PriSUD-Nordic-Diagnosing and Treating Substance Use Disorders in the Prison Population: Protocol for a Mixed Methods Study
   JMIR Res Protoc, 11 (3), e35182
   DOI 10.2196/35182, PubMed 35320114
5. Bukten A, Skjærvø I, Stavseth MR (2022)
   The association of prison security level with mortality after release from prison: a retrospective national cohort study (2000-16)
   Lancet Public Health, 7 (7), e583-e592
   DOI 10.1016/S2468-2667(22)00107-4, PubMed 35779542
6. Bækkelund H, Ulvenes P, Boon-Langelaan S, Arnevik EA (2022)
   Group treatment for complex dissociative disorders: a randomized clinical trial
   BMC Psychiatry, 22 (1), 338
   DOI 10.1186/s12888-022-03970-8, PubMed 35578194
7. Edvardsen HME, Aamodt C, Bogstrand ST, Krajci P, Vindenes V, Rognli EB (2022)
   Concentrations of psychoactive substances in blood samples from non-fatal and fatal opioid overdoses
   Br J Clin Pharmacol, 88 (10), 4494-4504
   DOI 10.1111/bcp.15365, PubMed 35470456
8. Finstad J, Clausen T, Rosseland LA, Røise O, Havnes IA (2022)
   Patient Experiences after Physical Trauma: The Negative Effect of the COVID-19 Pandemic on Recovery
   Int J Environ Res Public Health, 19 (19)
   DOI 10.3390/ijerph191912258, PubMed 36231553
9. Kildal E, Hassel B, Bjørnebekk A (2022)
   ADHD symptoms and use of anabolic androgenic steroids among male weightlifters
   Sci Rep, 12 (1), 9479
   DOI 10.1038/s41598-022-12977-w, PubMed 35676515
10. Lokdam NT, Stavseth MR, Bukten A (2022)
    Drug use and re-imprisonment: A prospective study of the Norwegian Offender Mental Health and Addiction (NorMA) cohort
    Drug Alcohol Depend Rep, 5, 100127
    DOI 10.1016/j.dadr.2022.100127, PubMed 36844156
11. Melsom HS, Heiestad CM, Eftestøl E, Torp MK, Gundersen K, Bjørnebekk AK, Thorsby PM, Stensløkken KO, Hisdal J (2022)
    Reduced arterial elasticity after anabolic-androgenic steroid use in young adult males and mice
    Sci Rep, 12 (1), 9707
    DOI 10.1038/s41598-022-14065-5, PubMed 35690664
12. Myhre MØ, Walby FA, Bramness JG, Mehlum L (2022)
    Trajectories of Service Contact before Suicide in People with Substance Use Disorders-A National Register Study
    Arch Suicide Res, 28 (1), 200-215
    DOI 10.1080/13811118.2022.2151959, PubMed 36472383
13. Pape H, Lobmaier P, Bukten A (2022)
    An evaluation of eight short versions of the Drug Use Disorder Identification Test (DUDIT). A prison population study
    Drug Alcohol Depend Rep, 3, 100043
    DOI 10.1016/j.dadr.2022.100043, PubMed 36845984
14. Rognli EB, Støme LN, Kværner KJ, Wilhelmsen C, Arnevik EA (2022)
    The effect of employment support integrated in substance use treatment: A health economic cost-effectiveness simulation of three different interventions
    Nordisk Alkohol Nark, 40 (2), 199-211
    DOI 10.1177/14550725221122196, PubMed 37063816
15. Rognli EB, Taipale H, Hjorthøj C, Mittendorfer-Rutz E, Bramness JG, Heiberg IH, Niemelä S (2022)
    Annual incidence of substance-induced psychoses in Scandinavia from 2000 to 2016
    Psychol Med, 53 (11), 5246-5255
    DOI 10.1017/S003329172200229X, PubMed 35983644
16. Scarth M, Havnes IA, Jørstad ML, McVeigh J, Van Hout MC, Westlye LT, Torgersen S, Bjørnebekk A (2022)
    Severity of anabolic steroid dependence, executive function, and personality traits in substance use disorder patients in Norway
    Drug Alcohol Depend, 231, 109275
    DOI 10.1016/j.drugalcdep.2022.109275, PubMed 35030506
17. Scarth M, Jørstad ML, Reierstad A, Klonteig S, Torgersen S, Hullstein IR, Bjørnebekk A (2022)
    Psychopathology among anabolic-androgenic steroid using and non-using female athletes in Norway
    J Psychiatr Res, 155, 295-301
    DOI 10.1016/j.jpsychires.2022.09.023, PubMed 36170757

Publications 2021

1. Bech AB, Clausen T, Waal H, Delaveris GJM, Skeie I (2021)
   Organ pathologies detected post-mortem in patients receiving opioid agonist treatment for opioid use disorder: a nation-wide 2-year cross-sectional study
   Addiction, 117 (4), 977-985
   DOI 10.1111/add.15705, PubMed 34648218
2. Bjørnebekk A, Kaufmann T, Hauger LE, Klonteig S, Hullstein IR, Westlye LT (2021)
   Long-term Anabolic-Androgenic Steroid Use Is Associated With Deviant Brain Aging
   Biol Psychiatry Cogn Neurosci Neuroimaging, 6 (5), 579-589
   DOI 10.1016/j.bpsc.2021.01.001, PubMed 33811018
3. Bukten A, Stavseth MR (2021)
   Suicide in prison and after release: a 17-year national cohort study
   Eur J Epidemiol, 36 (10), 1075-1083
   DOI 10.1007/s10654-021-00782-0, PubMed 34427828
4. Bækkelund H, Karlsrud I, Hoffart A, Arnevik EA (2021)
   Stabilizing group treatment for childhood-abuse related PTSD: a randomized controlled trial
   Eur J Psychotraumatol, 12 (1), 1859079
   DOI 10.1080/20008198.2020.1859079, PubMed 33537118
5. Ellingsen MM, Clausen T, Johannesen SL, Martinsen EW, Hallgren M (2021)
   Effects of acute exercise on drug craving in adults with poly-substance use disorder. A randomized controlled trial
   Ment. Health Phys. Act., 21, 100423
   DOI 10.1016/j.mhpa.2021.100423
6. Finstad J, Røise O, Rosseland LA, Clausen T, Havnes IA (2021)
   Discharge from the trauma centre: exposure to opioids, unmet information needs and lack of follow up-a qualitative study among physical trauma survivors
   Scand J Trauma Resusc Emerg Med, 29 (1), 121
   DOI 10.1186/s13049-021-00938-7, PubMed 34419130
7. Hauger LE, Havnes IA, Jørstad ML, Bjørnebekk A (2021)
   Anabolic androgenic steroids, antisocial personality traits, aggression and violence
   Drug Alcohol Depend, 221, 108604
   DOI 10.1016/j.drugalcdep.2021.108604, PubMed 33621808
8. Havnes IA, Muller AE (2021)
   Nonprescribed androgen use among women and trans men
   Curr Opin Endocrinol Diabetes Obes, 28 (6), 595-603
   DOI 10.1097/MED.0000000000000680, PubMed 34709214
9. Kvarstein EH, Zahl KE, Stänicke LI, Pettersen MS, Baltzersen ÅL, Johansen MS, Eikenaes IU, Arnevik EA, Hummelen B, Wilberg T, Pedersen G (2021)
   Vulnerability of personality disorder during the Covid-19 crises - a multicenter survey of treatment experiences among patients referred to treatment
   Nord J Psychiatry, 76 (1), 52-63
   DOI 10.1080/08039488.2021.1934110, PubMed 34126854
10. Midgard H, Ulstein K, Backe Ø, Foshaug T, Sørli H, Vennesland K, Nilssen D, Dahl EH, Finbråten AK, Wüsthoff L, Dalgard O (2021)
    Hepatitis C treatment and reinfection surveillance among people who inject drugs in a low-threshold program in Oslo, Norway
    Int J Drug Policy, 96, 103165
    DOI 10.1016/j.drugpo.2021.103165, PubMed 33642182
11. Rognli EB, Bramness JG, von Soest T (2021)
    Smoking in early adulthood is prospectively associated with prescriptions of antipsychotics, mood stabilizers, antidepressants and anxiolytics
    Psychol Med, 52 (14), 3241-3250
    DOI 10.1017/S0033291720005401, PubMed 33583454
12. Rognli EB, Aas EM, Drake RE, Marsden J, Anders P, Bond GR, Lystad JU, Reme SE, Arnevik EA (2021)
    The effect evaluation of Individual Placement and Support (IPS) for patients with substance use disorders: study protocol for a randomized controlled trial of IPS versus enhanced self-help
    Trials, 22 (1), 705
    DOI 10.1186/s13063-021-05673-z, PubMed 34654464
13. Scarth M, Bjørnebekk A (2021)
    Androgen abuse and the brain
    Curr Opin Endocrinol Diabetes Obes, 28 (6), 604-614
    DOI 10.1097/MED.0000000000000675, PubMed 34709215
14. Stavseth MR (2021)
    STATISTICAL DATA ANALYSIS OF 1-2-3
    Tidsskr. Nor. Laegeforen., 141 (3), 288
15. Walderhaug E (2021)
    From punishment to help?
    Tidsskr Nor Laegeforen, 141 (9)
    DOI 10.4045/tidsskr.21.0386, PubMed 34107660

Publications 2020

1. Bech AB, Clausen T, Waal H, Vindenes V, Edvardsen HE, Frost J, Skeie I (2020)
   Post-mortem toxicological analyses of blood samples from 107 patients receiving opioid agonist treatment: substances detected and pooled opioid and benzodiazepine concentrations
   Addiction, 116 (4), 845-855
   DOI 10.1111/add.15211, PubMed 32738014
2. Bramness JG, Bretteville-Jensen AL (2020)
   [Cannabis – riskier than we thought?]
   Tidsskr Nor Laegeforen, 140 (18)
   DOI 10.4045/tidsskr.20.0801, PubMed 33322880
3. Bramness JG, Malt UF (2020)
   [Gradual dose reduction of antipsychotic drugs]
   Tidsskr Nor Laegeforen, 140 (10)
   DOI 10.4045/tidsskr.20.0322, PubMed 32602326
4. Brorson HH, Arnevik EA, Rand-Hendriksen K, Duckert F (2020)
   Corrigendum to "Drop-out from addiction treatment: A systematic review of risk factors"
   Clin Psychol Rev, 76, 101796
   DOI 10.1016/j.cpr.2019.101796, PubMed 32067823
5. Bukten A, Lund IO, Kinner SA, Rognli EB, Havnes IA, Muller AE, Stavseth MR (2020)
   Factors associated with drug use in prison - results from the Norwegian offender mental health and addiction (NorMA) study
   Health Justice, 8 (1), 10
   DOI 10.1186/s40352-020-00112-8, PubMed 32399643
6. Ellingsen MM, Johannesen SL, Martinsen EW, Dahl SR, Hallgren M (2020)
   Effects of Acute Exercise on Drug Craving, Self-Esteem, Mood, and Affect in Adults with Polysubstance Use Disorder: Protocol for a Multicenter Randomized Controlled Trial
   JMIR Res Protoc, 9 (10), e18553
   DOI 10.2196/18553, PubMed 33048056
7. Gatti F, Walderhaug E, Kern-Godal A, Lysell J, Arnevik EA (2020)
   Complementary horse-assisted therapy for substance use disorders: a randomized controlled trial
   Addict Sci Clin Pract, 15 (1), 7
   DOI 10.1186/s13722-020-0183-z, PubMed 32019584
8. Hauger LE, Westlye LT, Bjørnebekk A (2020)
   Anabolic androgenic steroid dependence is associated with executive dysfunction
   Drug Alcohol Depend, 208, 107874
   DOI 10.1016/j.drugalcdep.2020.107874, PubMed 31972519
9. Havnes IA (2020)
   DOPING Addiction, vanity and performance
   Tidsskr. Nor. Laegeforen., 140 (5), 496
10. Havnes IA, Bukten A, Rognli EB, Muller AE (2020)
    Use of anabolic-androgenic steroids and other substances prior to and during imprisonment - Results from the Norwegian Offender Mental Health and Addiction (NorMA) study
    Drug Alcohol Depend, 217, 108255
    DOI 10.1016/j.drugalcdep.2020.108255, PubMed 32949884
11. Havnes IA, Jørstad ML, Innerdal I, Bjørnebekk A (2020)
    Anabolic-androgenic steroid use among women - A qualitative study on experiences of masculinizing, gonadal and sexual effects
    Int J Drug Policy, 95, 102876
    DOI 10.1016/j.drugpo.2020.102876, PubMed 32736958
12. Havnes IA, Jørstad ML, McVeigh J, Van Hout MC, Bjørnebekk A (2020)
    The Anabolic Androgenic Steroid Treatment Gap: A National Study of Substance Use Disorder Treatment
    Subst Abuse, 14, 1178221820904150
    DOI 10.1177/1178221820904150, PubMed 32127749
13. Medved D, Clausen T, Bukten A, Bjørnestad R, Muller AE (2020)
    Large and non-specific somatic disease burdens among ageing, long-term opioid maintenance treatment patients
    Subst Abuse Treat Prev Policy, 15 (1), 87
    DOI 10.1186/s13011-020-00311-4, PubMed 33198799
14. Mutsaerts HJMM, Petr J, Groot P, Vandemaele P, Ingala S, Robertson AD, Václavů L, Groote I, Kuijf H, Zelaya F, O'Daly O, Hilal S, Wink AM, Kant I, Caan MWA, Morgan C, de Bresser J, Lysvik E, Schrantee A, Bjørnebekk A, Clement P, Shirzadi Z, Kuijer JPA, Wottschel V, Anazodo UC et al. (2020)
    ExploreASL: An image processing pipeline for multi-center ASL perfusion MRI studies
    Neuroimage, 219, 117031
    DOI 10.1016/j.neuroimage.2020.117031, PubMed 32526385
15. Pape H, Rossow I, Bukten A (2020)
    Alcohol Problems among Prisoners: Subgroup Variations, Concurrent Drug Problems, and Treatment Needs
    Eur Addict Res, 27 (3), 179-188
    DOI 10.1159/000511253, PubMed 33321498
16. Paap MCS, Hummelen B, Braeken J, Arnevik EA, Walderhaug E, Wilberg T, Berghuis H, Hutsebaut J, Pedersen G (2020)
    A multi-center psychometric evaluation of the Severity Indices of Personality Problems 118 (SIPP-118): Do we really need all those facets?
    Qual Life Res, 30 (2), 567-575
    DOI 10.1007/s11136-020-02654-8, PubMed 33029679
17. Rand K, Arnevik EA, Walderhaug E (2020)
    Quality of life among patients seeking treatment for substance use disorder, as measured with the EQ-5D-3L
    J Patient Rep Outcomes, 4 (1), 92
    DOI 10.1186/s41687-020-00247-0, PubMed 33165764
18. Solli KK, Opheim A, Latif ZE, Krajci P, Benth JŠ, Kunoe N, Tanum L (2020)
    Adapting treatment length to opioid-dependent individuals' needs and preferences: A 2-year follow-up to a 1-year study of extended-release naltrexone
    Addiction, 116 (8), 2084-2093
    DOI 10.1111/add.15378, PubMed 33338285
19. Stavseth MR (2020)
    Sensitivity analysis - how robust is the result?
    Tidsskr. Nor. Laegeforen., 140 (8), 807
20. Tonga JB, Eilertsen DE, Solem IKL, Arnevik EA, Korsnes MS, Ulstein ID (2020)
    Effect of Self-Efficacy on Quality of Life in People With Mild Cognitive Impairment and Mild Dementia: The Mediating Roles of Depression and Anxiety
    Am J Alzheimers Dis Other Demen, 35, 1533317519885264
    DOI 10.1177/1533317519885264, PubMed 31916847
21. Tonga JB, Šaltytė Benth J, Arnevik EA, Werheid K, Korsnes MS, Ulstein ID (2020)
    Managing depressive symptoms in people with mild cognitive impairment and mild dementia with a multicomponent psychotherapy intervention: a randomized controlled trial
    Int Psychogeriatr, 33 (3), 217-231
    DOI 10.1017/S1041610220000216, PubMed 32131911
22. Vaskinn A, Hauger LE, Bjørnebekk A (2020)
    Theory of mind in users of anabolic androgenic steroids
    Psychopharmacology (Berl), 237 (10), 3191-3199
    DOI 10.1007/s00213-020-05603-y, PubMed 32623552
23. Welle-Strand GK, Skurtveit S, Abel KF, Chalabianloo F, Sarfi M (2020)
    Living a normal life? Follow-up study of women who had been in opioid maintenance treatment during pregnancy
    J Subst Abuse Treat, 113, 108004
    DOI 10.1016/j.jsat.2020.108004, PubMed 32359675
24. Waal H, Vold JH, Skurtveit SO (2020)
    Quetiapine abuse - myth or reality?
    Tidsskr. Nor. Laegeforen., 140 (12), 1228-1230

Publications 2019

1. Arnevik EA, Pedersen G, Walderhaug E, Lien I, Wilberg T, Hummelen B (2019)
   Measuring Personality Problems in Patients With Substance Use Disorders: A Cross-Sample Validation
   J Dual Diagn, 15 (4), 324-332
   DOI 10.1080/15504263.2019.1668583, PubMed 31571533
2. Bech AB, Clausen T, Waal H, Šaltytė Benth J, Skeie I (2019)
   Mortality and causes of death among patients with opioid use disorder receiving opioid agonist treatment: a national register study
   BMC Health Serv Res, 19 (1), 440
   DOI 10.1186/s12913-019-4282-z, PubMed 31266495
3. Bramness JG (2019)
   [No easy access to health data]
   Tidsskr Nor Laegeforen, 139 (8)
   DOI 10.4045/tidsskr.19.0234, PubMed 31062559
4. Bramness JG, Vindenes V (2019)
   [Medical cannabis]
   Tidsskr Nor Laegeforen, 139 (15)
   DOI 10.4045/tidsskr.19.0595, PubMed 31642634
5. Brorson HH, Arnevik EA, Rand K (2019)
   Predicting Dropout from Inpatient Substance Use Disorder Treatment: A Prospective Validation Study of the OQ-Analyst
   Subst Abuse, 13, 1178221819866181
   DOI 10.1177/1178221819866181, PubMed 31452601
6. Hauger LE, Sagoe D, Vaskinn A, Arnevik EA, Leknes S, Jørstad ML, Bjørnebekk A (2019)
   Anabolic androgenic steroid dependence is associated with impaired emotion recognition
   Psychopharmacology (Berl), 236 (9), 2667-2676
   DOI 10.1007/s00213-019-05239-7, PubMed 30941469
7. Hauger LE, Westlye LT, Fjell AM, Walhovd KB, Bjørnebekk A (2019)
   Structural brain characteristics of anabolic-androgenic steroid dependence in men
   Addiction, 114 (8), 1405-1415
   DOI 10.1111/add.14629, PubMed 30955206
8. Havnes IA, Jørstad ML, Wisløff C (2019)
   Anabolic-androgenic steroid users receiving health-related information; health problems, motivations to quit and treatment desires
   Subst Abuse Treat Prev Policy, 14 (1), 20
   DOI 10.1186/s13011-019-0206-5, PubMed 31096999
9. Helverschou SB, Brunvold AR, Arnevik EA (2019)
   Treating Patients With Co-occurring Autism Spectrum Disorder and Substance Use Disorder: A Clinical Explorative Study
   Subst Abuse, 13, 1178221819843291
   DOI 10.1177/1178221819843291, PubMed 31024216
10. Latif ZE, Šaltyte Benth J, Solli KK, Opheim A, Kunoe N, Krajci P, Sharma-Haase K, Tanum L (2019)
    Anxiety, Depression, and Insomnia Among Adults With Opioid Dependence Treated With Extended-Release Naltrexone vs Buprenorphine-Naloxone: A Randomized Clinical Trial and Follow-up Study
    JAMA Psychiatry, 76 (2), 127-134
    DOI 10.1001/jamapsychiatry.2018.3537, PubMed 30566177
11. Latif ZE, Solli KK, Opheim A, Kunoe N, Benth JŠ, Krajci P, Sharma-Haase K, Tanum L (2019)
    No increased pain among opioid-dependent individuals treated with extended-release naltrexone or buprenorphine-naloxone: A 3-month randomized study and 9-month open-treatment follow-up study
    Am J Addict, 28 (2), 77-85
    DOI 10.1111/ajad.12859, PubMed 30701613
12. Morland J, Waal H (2019)
    "The entire common catalog" in the treatment of drug disorders
    Tidsskr. Nor. Laegeforen., 139 (3), 240-242
13. Muller AE, Bukten A (2019)
    Measuring the quality of life of incarcerated individuals
    Int J Prison Health, 15 (1), 1-13
    DOI 10.1108/IJPH-02-2018-0005, PubMed 30827162
14. Pedersen G, Arnevik EA, Hummelen B, Walderhaug E, Wilberg T (2019)
    Psychometric Properties of the Severity Indices of Personality Problems (SIPP) in Two Samples A Norwegian Community Sample and Clinical Samples of Patients With and Without Personality Disorders
    Eur. J. Psychol. Assess., 35 (5), 698-711
    DOI 10.1027/1015-5759/a000436
15. Pettersen H, Brodahl M, Rundgren J, Davidson L, Havnes IA (2019)
    Partnering with persons in long-term recovery from substance use disorder: experiences from a collaborative research project
    Harm Reduct J, 16 (1), 40
    DOI 10.1186/s12954-019-0310-x, PubMed 31234878
16. Rognli EB, Bramness JG, von Soest T (2019)
    Cannabis use in early adulthood is prospectively associated with prescriptions of antipsychotics, mood stabilizers, and antidepressants
    Acta Psychiatr Scand, 141 (2), 149-156
    DOI 10.1111/acps.13104, PubMed 31560790
17. Solli KK, Kunoe N, Latif ZE, Sharma-Haase K, Opheim A, Krajci P, Gaulen Z, Šaltytė Benth J, Tanum L (2019)
    Availability of Extended-Release Naltrexone May Increase the Number of Opioid-Dependent Individuals in Treatment: Extension of a Randomized Clinical Trial
    Eur Addict Res, 25 (6), 303-309
    DOI 10.1159/000501931, PubMed 31340204
18. Sømhovd M, Hagen E, Bergly T, Arnevik EA (2019)
    The Montreal Cognitive Assessment as a predictor of dropout from residential substance use disorder treatment
    Heliyon, 5 (3), e01282
    DOI 10.1016/j.heliyon.2019.e01282, PubMed 31025003
19. Walderhaug E, Seim-Wikse KJ, Enger A, Milin O (2019)
    Polydrug Use - prevalence and registration
    Tidsskr. Nor. Laegeforen., 139 (13), 1279-1281
20. Walderhaug E, Seim-Wikse KJ, Enger A, Milin O (2019)
    Polydrug use - prevalence and registration
    Tidsskr Nor Laegeforen, 139 (13)
    DOI 10.4045/tidsskr.19.0251, PubMed 31556532

Publications 2018

1. Andersson HW, Steinsbekk A, Walderhaug E, Otterholt E, Nordfjærn T (2018)
   Predictors of Dropout From Inpatient Substance Use Treatment: A Prospective Cohort Study
   Subst Abuse, 12, 1178221818760551
   DOI 10.1177/1178221818760551, PubMed 29531472
2. Bækkelund H, Frewen P, Lanius R, Ottesen Berg A, Arnevik EA (2018)
   Trauma-related altered states of consciousness in post-traumatic stress disorder patients with or without comorbid dissociative disorders
   Eur J Psychotraumatol, 9 (1), 1544025
   DOI 10.1080/20008198.2018.1544025, PubMed 30455853
3. Ellingsen MM, Johannesen SL, Martinsen EW, Hallgren M (2018)
   Effects of acute exercise on drug craving, self-esteem, mood and affect in adults with poly-substance dependence: Feasibility and preliminary findings
   Drug Alcohol Rev, 37 (6), 789-793
   DOI 10.1111/dar.12818, PubMed 29869351
4. Fosen JT, Høiseth G, Sempio C, Giarratana N, Enger A, Mørland J, Morini L (2018)
   Hair EtG: Alterations in segment levels accompanying hair growth
   Drug Test Anal, 11 (1), 112-118
   DOI 10.1002/dta.2474, PubMed 30084156
5. Gjerden P, Bramness JG, Slørdal L (2018)
   Kvetiapin brukes for mye
   Tidsskr Nor Laegeforen, 138 (13)
   DOI 10.4045/tidsskr.18.0535, PubMed 30180497
6. Hagen E, Sømhovd M, Hesse M, Arnevik EA, Erga AH (2018)
   Measuring cognitive impairment in young adults with polysubstance use disorder with MoCA or BRIEF-A - The significance of psychiatric symptoms
   J Subst Abuse Treat, 97, 21-27
   DOI 10.1016/j.jsat.2018.11.010, PubMed 30577896
7. Heldal AT, Skurtveit S, Lobmaier PPK, Vederhus JK, Bramness JG (2018)
   [Use of drugs for alcohol use disorder in Norway 2004–16]
   Tidsskr Nor Laegeforen, 138 (18)
   DOI 10.4045/tidsskr.18.0383, PubMed 30421743
8. Henriksen K, Jacobsen JA, Henriksen EM, Gomes L, Waal H, Krajci P (2018)
   The LASSO Program in Oslo: Harm Reduction Using Buprenorphine-Naloxone (Suboxone®) in a Low Threshold Setting
   Eur Addict Res, 24 (6), 286-292
   DOI 10.1159/000495188, PubMed 30466108
9. Haabrekke K, Siqveland T, Nygaaard E, Bjornebekk A, Slinning K, Wentzel-Larsen T, Walhovd KB, Smith L, Moe V (2018)
   COGNITIVE AND SOCIOEMOTIONAL FUNCTIONING AT 4½ YEARS IN CHILDREN BORN TO MOTHERS WHO HAVE RECEIVED TREATMENT FOR SUBSTANCE-ABUSE PROBLEMS WHILE PREGNANT
   Infant Ment Health J, 39 (5), 581-594
   DOI 10.1002/imhj.21733, PubMed 30084491
10. Jørstad ML, Skogheim TS, Bergsund HB (2018)
    “Mer hjelp, mindre moralpreken”: Hva brukere av anabole-androgene steroider ønsker fra helsetjenestene
    Nordisk Alkohol Nark, 35 (1), 69-76
    DOI 10.1177/1455072517748871, PubMed 32934514
11. Madah-Amiri D, Skulberg AK, Braarud AC, Dale O, Heyerdahl F, Lobmaier P, Clausen T (2018)
    Ambulance-attended opioid overdoses: An examination into overdose locations and the role of a safe injection facility
    Subst Abus, 40 (3), 383-388
    DOI 10.1080/08897077.2018.1485130, PubMed 29949448
12. Muller AE, Havnes IA, Rognli EB, Bukten A (2018)
    Inmates with Harmful Substance Use Increase Both Exercise and Nicotine Use Under Incarceration
    Int J Environ Res Public Health, 15 (12)
    DOI 10.3390/ijerph15122663, PubMed 30486386
13. Ringen PA, Faerden A, Antonsen B, Falk RS, Mamen A, Rognli EB, Solberg DK, Andreassen OA, Martinsen EW (2018)
    Cardiometabolic risk factors, physical activity and psychiatric status in patients in long-term psychiatric inpatient departments
    Nord J Psychiatry, 72 (4), 296-302
    DOI 10.1080/08039488.2018.1449012, PubMed 29523041
14. Ringen PA, Falk RS, Antonsen B, Faerden A, Mamen A, Rognli EB, Solberg DK, Martinsen EW, Andreassen OA (2018)
    Using motivational techniques to reduce cardiometabolic risk factors in long term psychiatric inpatients: a naturalistic interventional study
    BMC Psychiatry, 18 (1), 255
    DOI 10.1186/s12888-018-1832-6, PubMed 30111298
15. Solli KK, Latif ZE, Opheim A, Krajci P, Sharma-Haase K, Benth JŠ, Tanum L, Kunoe N (2018)
    Effectiveness, safety and feasibility of extended-release naltrexone for opioid dependence: a 9-month follow-up to a 3-month randomized trial
    Addiction, 113 (10), 1840-1849
    DOI 10.1111/add.14278, PubMed 29806872

Publications 2017

1. Bukten A, Stavseth MR, Skurtveit S, Tverdal A, Strang J, Clausen T (2017)
   High risk of overdose death following release from prison: variations in mortality during a 15-year observation period
   Addiction, 112 (8), 1432-1439
   DOI 10.1111/add.13803, PubMed 28319291
2. Fosen JT, Morini L, Sempio C, Giarratana N, Enger A, Mørland J, Høiseth G (2017)
   Ethyl Glucuronide Elimination Kinetics in Fingernails and Comparison to Levels in Hair
   Alcohol Alcohol, 52 (5), 580-586
   DOI 10.1093/alcalc/agx035, PubMed 28591773
3. Hagen E, Erga AH, Hagen KP, Nesvåg SM, McKay JR, Lundervold AJ, Walderhaug E (2017)
   One-year sobriety improves satisfaction with life, executive functions and psychological distress among patients with polysubstance use disorder
   J Subst Abuse Treat, 76, 81-87
   DOI 10.1016/j.jsat.2017.01.016, PubMed 28159440
4. Hagen E, Erga AH, Nesvåg SM, McKay JR, Lundervold AJ, Walderhaug E (2017)
   One-year abstinence improves ADHD symptoms among patients with polysubstance use disorder
   Addict Behav Rep, 6, 96-101
   DOI 10.1016/j.abrep.2017.08.005, PubMed 29450242
5. Kjoesnes R, Waal H, Hauff E, Gossop M (2017)
   Severe trauma among substance users in opioid maintenance treatment: users' assessment of worst trauma and clinical assessment of PTSD
   Heroin Addict. Relat. Clin. Probl., 19 (1), 5-11
6. Madah-Amiri D, Clausen T, Lobmaier P (2017)
   Rapid widespread distribution of intranasal naloxone for overdose prevention
   Drug Alcohol Depend, 173, 17-23
   DOI 10.1016/j.drugalcdep.2016.12.013, PubMed 28182982
7. Nyhagen HT, Waal H (2017)
   Den aldrende LAR pasienten
   Nordisk Alkohol Nark, 34 (1), 72-79
   DOI 10.1177/1455072516682637, PubMed 32934468
8. Tanum L, Solli KK, Latif ZE, Benth JŠ, Opheim A, Sharma-Haase K, Krajci P, Kunøe N (2017)
   Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial
   JAMA Psychiatry, 74 (12), 1197-1205
   DOI 10.1001/jamapsychiatry.2017.3206, PubMed 29049469
9. Wright N, Reimer J, Somaini L, Roncero C, Maremmani I, Simon N, Krajci P, Littlewood R, D'Agnone O, Alho H, Rolland B (2017)
   Are we ready to treat hepatitis C virus in individuals with opioid use disorder: assessment of readiness in European countries on the basis of an expert-generated model
   Eur J Gastroenterol Hepatol, 29 (11), 1206-1214
   DOI 10.1097/MEG.0000000000000962, PubMed 28914697

Publications 2016

1. Arnevik EA, Helverschou SB (2016)
   Autism Spectrum Disorder and Co-occurring Substance Use Disorder - A Systematic Review
   Subst Abuse, 10, 69-75
   DOI 10.4137/SART.S39921, PubMed 27559296
2. Bramness JG, Rognli EB (2016)
   Psychosis induced by amphetamines
   Curr Opin Psychiatry, 29 (4), 236-41
   DOI 10.1097/YCO.0000000000000254, PubMed 27175554
3. Hagen E, Erga AH, Hagen KP, Nesvåg SM, McKay JR, Lundervold AJ, Walderhaug E (2016)
   Assessment of Executive Function in Patients With Substance Use Disorder: A Comparison of Inventory- and Performance-Based Assessment
   J Subst Abuse Treat, 66, 1-8
   DOI 10.1016/j.jsat.2016.02.010, PubMed 27211990
4. Henriksen K, Waal H, Krajci P (2016)
   Will non-compliant 'hard-to-treat' opioid-dependent patients profit from low threshold methadone treatment? A prospective 15-month evaluation of patients on Low Dosage Methadone treatment at Oslo University Hospital
   Heroin Addict. Relat. Clin. Probl., 18 (3), 23-27
5. Kern-Godal A, Brenna IH, Arnevik EA, Ravndal E (2016)
   More Than Just a Break from Treatment: How Substance Use Disorder Patients Experience the Stable Environment in Horse-Assisted Therapy
   Subst Abuse, 10, 99-108
   DOI 10.4137/SART.S40475, PubMed 27746677
6. Kern-Godal A, Brenna IH, Kogstad N, Arnevik EA, Ravndal E (2016)
   Contribution of the patient-horse relationship to substance use disorder treatment: Patients' experiences
   Int J Qual Stud Health Well-being, 11, 31636
   DOI 10.3402/qhw.v11.31636, PubMed 27291162
7. Lien IA, Arnevik EA (2016)
   Assessment of personality problems among patients with substance use disorders
   Nord. Stud. Alcohol Drugs, 33 (4), 399-414
   DOI 10.1515/nsad-2016-0033
8. Madah-Amiri D, Clausen T, Lobmaier P (2016)
   Utilizing a train-the-trainer model for multi-site naloxone distribution programs
   Drug Alcohol Depend, 163, 153-6
   DOI 10.1016/j.drugalcdep.2016.04.007, PubMed 27107847
9. Madah-Amiri D, Clausen T, Myrmel L, Brattebø G, Lobmaier P (2016)
   Circumstances surrounding non-fatal opioid overdoses attended by ambulance services
   Drug Alcohol Rev, 36 (3), 288-294
   DOI 10.1111/dar.12451, PubMed 28036135
10. Maremmani I, Rolland B, Somaini L, Roncero C, Reimer J, Wright N, Littlewood R, Krajci P, Alho H, D'Agnone O, Simon N (2016)
    Buprenorphine dosing choices in specific populations: review of expert opinion
    Expert Opin Pharmacother, 17 (13), 1727-31
    DOI 10.1080/14656566.2016.1209486, PubMed 27376622
11. Nordheim K, Walderhaug E, Alstadius S, Kern-Godal A, Arnevik E, Duckert F (2016)
    Young adults' reasons for dropout from residential substance use disorder treatment
    Qual Soc Work, 17 (1), 24-40
    DOI 10.1177/1473325016654559, PubMed 29276430
12. Rognli EB, Bramness JG, Skurtveit S, Bukten A (2016)
    Substance use and sociodemographic background as risk factors for lifetime psychotic experiences in a non-clinical sample
    J Subst Abuse Treat, 74, 42-47
    DOI 10.1016/j.jsat.2016.12.007, PubMed 28132699
13. Westlye LT, Kaufmann T, Alnæs D, Hullstein IR, Bjørnebekk A (2016)
    Brain connectivity aberrations in anabolic-androgenic steroid users
    Neuroimage Clin, 13, 62-69
    DOI 10.1016/j.nicl.2016.11.014, PubMed 27942448

Publications 2015

1. Alho H, D'Agnone O, Krajci P, McKeganey N, Maremmani I, Reimer J, Roncero C, Somaini L, Wright N, Littlewood R (2015)
   The extent of misuse and diversion of medication for agonist opioid treatment: A review and expert opinions
   Heroin Addict. Relat. Clin. Probl., 17 (2-3), 25-33
2. Alho H, Jansen J, Krajci P, Littlewood R, Runarsdottir V, Nyberg F (2015)
   Misuse and diversion of agonist opioid treatment medicines: assessment of the scale of the problem and review of the changing environment for care in the Nordic countries
   Heroin Addict. Relat. Clin. Probl., 17 (5), 43-49
3. Bernard JP, Khiabani HZ, Hilberg T, Karinen R, Slørdal L, Waal H, Mørland J (2015)
   Characteristics of methadone-related fatalities in Norway
   J Forensic Leg Med, 36, 114-20
   DOI 10.1016/j.jflm.2015.09.011, PubMed 26439870
4. Bramness JG, Henriksen B, Person O, Mann K (2015)
   Reply: To PMID 23921359
   Eur Addict Res, 21 (1), 32
   PubMed 25621344
5. Bukten A, Lund IO, Rognli EB, Stavseth MR, Lobmaier P, Skurtveit S, Clausen T, Kunøe N (2015)
   The Norwegian Offender Mental Health and Addiction Study - Design and Implementation of a National Survey and Prospective Cohort Study
   Subst Abuse, 9 (Suppl 2), 59-66
   DOI 10.4137/SaRt.S23546, PubMed 26648732
6. Gaasland A, Havnes IA, Venberget M, Andresen JF (2015)
   [Re: All suicides are not due to treatment failure]
   Tidsskr Nor Laegeforen, 135 (18), 1625
   DOI 10.4045/tidsskr.15.0964, PubMed 26442723
7. Kern-Godal A, Arnevik EA, Walderhaug E, Ravndal E (2015)
   Substance use disorder treatment retention and completion: a prospective study of horse-assisted therapy (HAT) for young adults
   Addict Sci Clin Pract, 10, 21
   DOI 10.1186/s13722-015-0043-4, PubMed 26466788
8. Medhus S, Rognli EB, Gossop M, Holm B, Mørland J, Bramness JG (2015)
   Amphetamine-induced psychosis: Transition to schizophrenia and mortality in a small prospective sample
   Am J Addict, 24 (7), 586-9
   DOI 10.1111/ajad.12274, PubMed 26332037
9. Nordal K, Øiestad EL, Enger A, Christophersen AS, Vindenes V (2015)
   Detection Times of Diazepam, Clonazepam, and Alprazolam in Oral Fluid Collected From Patients Admitted to Detoxification, After High and Repeated Drug Intake
   Ther Drug Monit, 37 (4), 451-60
   DOI 10.1097/FTD.0000000000000174, PubMed 25549207
10. Opdal MS, Arnesen M, Müller LD, Hullstein I, Sayed K, Brørs O, Kringen M, Sagedal S, Gjesdal K, Krajci P (2015)
    Effects of Hemodialysis on Methadone Pharmacokinetics and QTc
    Clin Ther, 37 (7), 1594-9
    DOI 10.1016/j.clinthera.2015.04.009, PubMed 25963997
11. Reimer J, Wright N, Somaini L, Roncero C, Maremmani I, McKeganey N, Littlewood R, Krajci P, Alho H, D'Agnone O (2015)
    The Impact of Misuse and Diversion of Opioid Substitution Treatment Medicines: Evidence Review and Expert Consensus
    Eur Addict Res, 22 (2), 99-106
    DOI 10.1159/000438988, PubMed 26426530
12. Rognli EB, Berge J, Håkansson A, Bramness JG (2015)
    Long-term risk factors for substance-induced and primary psychosis after release from prison. A longitudinal study of substance users
    Schizophr Res, 168 (1-2), 185-90
    DOI 10.1016/j.schres.2015.08.032, PubMed 26359848
13. Wright N, D'Agnone O, Krajci P, Littlewood R, Alho H, Reimer J, Roncero C, Somaini L, Maremmani I (2015)
    Addressing misuse and diversion of opioid substitution medication: guidance based on systematic evidence review and real-world experience
    J Public Health (Oxf), 38 (3), e368-e374
    DOI 10.1093/pubmed/fdv150, PubMed 26508767

Publications 2014

1. Abel KF, Bramness JG, Martinsen EW (2014)
   Stimulant medication for ADHD in opioid maintenance treatment
   J Dual Diagn, 10 (1), 32-8
   DOI 10.1080/15504263.2013.867657, PubMed 25392060
2. Andås HT, Krabseth HM, Enger A, Marcussen BN, Haneborg AM, Christophersen AS, Vindenes V, Øiestad EL (2014)
   Detection time for THC in oral fluid after frequent cannabis smoking
   Ther Drug Monit, 36 (6), 808-14
   DOI 10.1097/FTD.0000000000000092, PubMed 24819969
3. Havnes IA, Clausen T, Brux C, Middelthon AL (2014)
   The role of substance use and morality in violent crime - a qualitative study among imprisoned individuals in opioid maintenance treatment
   Harm Reduct J, 11, 24
   DOI 10.1186/1477-7517-11-24, PubMed 25142321
4. Havnes IA, Clausen T, Middelthon AL (2014)
   Execution of control among 'non-compliant', imprisoned individuals in opioid maintenance treatment
   Int J Drug Policy, 25 (3), 480-5
   DOI 10.1016/j.drugpo.2014.01.018, PubMed 24594221
5. Kunøe N, Lobmaier P, Ngo H, Hulse G (2014)
   Injectable and implantable sustained release naltrexone in the treatment of opioid addiction
   Br J Clin Pharmacol, 77 (2), 264-71
   DOI 10.1111/bcp.12011, PubMed 23088328
6. Pettersen H, Ruud T, Ravndal E, Havnes I, Landheim A (2014)
   Engagement in assertive community treatment as experienced by recovering clients with severe mental illness and concurrent substance use
   Int J Ment Health Syst, 8 (1), 40
   DOI 10.1186/1752-4458-8-40, PubMed 25389446
7. Tveito M, Bramness JG, Engedal K, Lorentzen B, Refsum H, Høiseth G (2014)
   Psychotropic medication in geriatric psychiatric patients: use and unreported use in relation to serum concentrations
   Eur J Clin Pharmacol, 70 (9), 1139-45
   DOI 10.1007/s00228-014-1720-z, PubMed 25031073
8. Waal H (2014)
   [Advances in the detention cell]
   Tidsskr Nor Laegeforen, 134 (3), 263
   DOI 10.4045/tidsskr.14.0015, PubMed 24518445

Publications 2013

1. Havnes IA, Clausen T, Middelthon AL (2013)
   'Diversion' of methadone or buprenorphine: 'harm' versus 'helping'
   Harm Reduct J, 10, 24
   DOI 10.1186/1477-7517-10-24, PubMed 24131626
2. Helseth V, Samet S, Johnsen J, Bramness JG, Waal H (2013)
   Independent or Substance-Induced Mental Disorders? An Investigation of Comorbidity in an Acute Psychiatric Unit
   J. Dual Diagn., 9 (1), 78-86
   DOI 10.1080/15504263.2012.749142
3. Westin AA, Bramness JG, Chalabianloo F, Slørdal L (2013)
   [A. A. Westin and colleagues reply]
   Tidsskr Nor Laegeforen, 133 (10), 1045-6
   DOI 10.4045/tidsskr.13.0619, PubMed 23712142

Publications 2012

1. Bernard JP, Havnes I, Slørdal L, Waal H, Mørland J, Khiabani HZ (2012)
   Methadone-related deaths in Norway
   Forensic Sci Int, 224 (1-3), 111-6
   DOI 10.1016/j.forsciint.2012.11.010, PubMed 23246070
2. Pedersen K, Waal H, Kringlen E (2012)
   Patients with nonaffective psychosis are at increased risk for heroin use disorders
   Eur Addict Res, 18 (3), 124-9
   DOI 10.1159/000334613, PubMed 22354141
3. Skeie I, Brekke M, Clausen T, Gossop M, Lindbaek M, Reinertsen E, Thoresen M, Waal H (2012)
   Increased somatic morbidity in the first year after leaving opioid maintenance treatment: results from a Norwegian cohort study
   Eur Addict Res, 19 (4), 194-201
   DOI 10.1159/000345229, PubMed 23257574
4. Waal H, Brekke M, Clausen T, Lindbæk M, Rosta J, Skeie I, Aasland OG (2012)
   General practitioners' views on drug-assisted rehabilitation
   Tidsskr Nor Laegeforen, 132 (16), 1861-6
   DOI 10.4045/tidsskr.12.0124, PubMed 22986970

Publications 2011

1. Bukten A, Skurtveit S, Gossop M, Waal H, Stangeland P, Havnes I, Clausen T (2011)
   Engagement with opioid maintenance treatment and reductions in crime: a longitudinal national cohort study
   Addiction, 107 (2), 393-9
   DOI 10.1111/j.1360-0443.2011.03637.x, PubMed 21883606
2. Bukten A, Skurtveit S, Stangeland P, Gossop M, Willersrud AB, Waal H, Havnes I, Clausen T (2011)
   Criminal convictions among dependent heroin users during a 3-year period prior to opioid maintenance treatment: a longitudinal national cohort study
   J Subst Abuse Treat, 41 (4), 407-14
   DOI 10.1016/j.jsat.2011.06.006, PubMed 21839605
3. Helland A, Bramness JG (2011)
   [Baclofen for alcohol addiction]
   Tidsskr Nor Laegeforen, 131 (21), 2132-3
   DOI 10.4045/tidsskr.11.0584, PubMed 22048211
4. Lobmaier PP, Kunøe N, Gossop M, Waal H (2011)
   Naltrexone depot formulations for opioid and alcohol dependence: a systematic review
   CNS Neurosci Ther, 17 (6), 629-36
   DOI 10.1111/j.1755-5949.2010.00194.x, PubMed 21554565
5. Mordal J, Holm B, Gossop M, Romøren M, Mørland J, Bramness J (2011)
   Psychoactive substance use among patients admitted to an acute psychiatric ward: laboratory findings and associations with clinical characteristics
   Nord J Psychiatry, 65 (3), 208-15
   DOI 10.3109/08039488.2010.527014, PubMed 21047195
6. Skeie I, Brekke M, Gossop M, Lindbaek M, Reinertsen E, Thoresen M, Waal H (2011)
   Changes in somatic disease incidents during opioid maintenance treatment: results from a Norwegian cohort study
   BMJ Open, 1 (1), e000130
   DOI 10.1136/bmjopen-2011-000130, PubMed 22021771
7. Vindenes V, Yttredal B, Oiestad EL, Waal H, Bernard JP, Mørland JG, Christophersen AS (2011)
   Oral fluid is a viable alternative for monitoring drug abuse: detection of drugs in oral fluid by liquid chromatography-tandem mass spectrometry and comparison to the results from urine samples from patients treated with Methadone or Buprenorphine
   J Anal Toxicol, 35 (1), 32-9
   DOI 10.1093/anatox/35.1.32, PubMed 21219701

Publications 2010

1. Bramness JG (2010)
   [Abuse of pregabalin]
   Tidsskr Nor Laegeforen, 130 (17), 1703-4
   DOI 10.4045/tidsskr.10.0834, PubMed 20835274
2. Bramness JG, Clausen T, Duckert F, Ravndal E, Waal H (2010)
   Addiction research centres and the nurturing of creativity The Norwegian Centre for Addiction Research (SERAF)
   Addiction, 106 (8), 1381-5
   DOI 10.1111/j.1360-0443.2010.03086.x, PubMed 20735364
3. Brekke M, Vetlesen A, Høiby L, Skeie I (2010)
   [Quality of life among patients in drug-assisted rehabilitation programmes]
   Tidsskr Nor Laegeforen, 130 (13), 1340-2
   DOI 10.4045/tidsskr.09.1117, PubMed 20596114
4. Kornør H, Pedersen W, von Soest T, Rossow I, Bramness JG (2010)
   [Use of benzodiazepines and cannabis in young adults]
   Tidsskr Nor Laegeforen, 130 (9), 928-31
   DOI 10.4045/tidsskr.09.0188, PubMed 20453954
5. Lobmaier P, Gossop M, Waal H, Bramness J (2010)
   The pharmacological treatment of opioid addiction--a clinical perspective
   Eur J Clin Pharmacol, 66 (6), 537-45
   DOI 10.1007/s00228-010-0793-6, PubMed 20169438
6. Lobmaier PP, Kunøe N, Gossop M, Katevoll T, Waal H (2010)
   Naltrexone implants compared to methadone: outcomes six months after prison release
   Eur Addict Res, 16 (3), 139-45
   DOI 10.1159/000313336, PubMed 20424458
7. Ravndal E, Amundsen EJ (2010)
   Mortality among drug users after discharge from inpatient treatment: an 8-year prospective study
   Drug Alcohol Depend, 108 (1-2), 65-9
   DOI 10.1016/j.drugalcdep.2009.11.008, PubMed 20022184
8. Ravndal E, Vaglum P (2010)
   The Millon Clinical Multiaxial Inventory II: stability over time? A seven-year follow-up study of substance abusers in treatment
   Eur Addict Res, 16 (3), 146-51
   DOI 10.1159/000313337, PubMed 20424459
9. Waal H (2010)
   NISUD—progress, backlash or sidetrack?
   Addiction, 105 (12), 2050-1; discussion 2056
   DOI 10.1111/j.1360-0443.2010.03116.x, PubMed 21105301
10. Waal H, Bramness JG (2010)
    [Benzodiazepines to people with substance abuse problems?]
    Tidsskr Nor Laegeforen, 130 (6), 610-2
    DOI 10.4045/tidsskr.09.0687, PubMed 20349006

Publications 2009

1. Bramness JG (2009)
   [Adolescents and everyday life pains]
   Tidsskr Nor Laegeforen, 129 (15), 1444
   DOI 10.4045/tidsskr.09.0691, PubMed 19690589
2. Bramness JG, Walby F (2009)
   Ecological studies and the big puzzle of falling suicide rates
   Acta Psychiatr Scand, 119 (3), 169-70
   DOI 10.1111/j.1600-0447.2008.01318.x, PubMed 19178393
3. Clausen T, Havnes IA, Waal H (2009)
   [Overdose statistics--a complicated account]
   Tidsskr Nor Laegeforen, 129 (21), 2233-6
   DOI 10.4045/tidsskr.08.0605, PubMed 19898571
4. Shaygani S, Waal H (2009)
   [Treatment of opioid withdrawal]
   Tidsskr Nor Laegeforen, 129 (2), 114-5
   DOI 10.4045/tidsskr.09.32466, PubMed 19151804
5. Winther RB, Bramness JG (2009)
   [Prescription shopping of addictive drugs in Norway]
   Tidsskr Nor Laegeforen, 129 (6), 517-20
   DOI 10.4045/tidsskr.09.34414, PubMed 19282887

Publications 2008

1. Bramness JG (2008)
   [The Somadril Association in Norway]
   Tidsskr Nor Laegeforen, 128 (13), 1545; authorr reply 1545
   PubMed 18587468
2. Gustavsen I, Bramness JG, Skurtveit S, Engeland A, Neutel I, Mørland J (2008)
   Road traffic accident risk related to prescriptions of the hypnotics zopiclone, zolpidem, flunitrazepam and nitrazepam
   Sleep Med, 9 (8), 818-22
   DOI 10.1016/j.sleep.2007.11.011, PubMed 18226959
3. Hausken AM, Furu K, Skurtveit S, Engeland A, Bramness JG (2008)
   Starting insomnia treatment: the use of benzodiazepines versus z-hypnotics. A prescription database study of predictors
   Eur J Clin Pharmacol, 65 (3), 295-301
   DOI 10.1007/s00228-008-0565-8, PubMed 18810397
4. Skeie I, Brekke M, Lindbaek M, Waal H (2008)
   Somatic health among heroin addicts before and during opioid maintenance treatment: a retrospective cohort study
   BMC Public Health, 8, 43
   DOI 10.1186/1471-2458-8-43, PubMed 18237421
5. Slørdal L, Bramness JG (2008)
   [Is alimemazine a suitable sleeping agent for children?]
   Tidsskr Nor Laegeforen, 128 (19), 2194-6
   PubMed 18846144

Publications 2007

1. Bramness JG, Sandvik P, Schøyen H, Walby FA (2007)
   [Weak report about antidepressive agents from the Knowledge Center]
   Tidsskr Nor Laegeforen, 127 (24), 3236-7
   PubMed 18084369
2. Hausken AM, Skurtveit S, Rosvold EO, Bramness JG, Furu K (2007)
   Psychotropic drug use among persons with mental distress symptoms: a population-based study in Norway
   Scand J Public Health, 35 (4), 356-64
   DOI 10.1080/14034940601159161, PubMed 17786798
3. Kornør H, Waal H, Sandvik L (2007)
   Time-limited buprenorphine replacement therapy for opioid dependence: 2-year follow-up outcomes in relation to programme completion and current agonist therapy status
   Drug Alcohol Rev, 26 (2), 135-41
   DOI 10.1080/09595230601146603, PubMed 17364848
4. Kunøe N, Waal H (2007)
   Opioid overdose deaths can occur in patients with naltrexone implants
   Med J Aust, 187 (1), 56; author reply 56-7
   DOI 10.5694/j.1326-5377.2007.tb01124.x, PubMed 17605713
5. Pedersen K, Sandvik L, Waal H (2007)
   Evaluation of DTES - A simple drug-taking scale
   Addict. Res. Theory, 15 (6), 637-649
   DOI 10.1080/16066350701433209
6. Skeie I, Brekke M, Lindbaek M, Waal H (2007)
   [General practitioners can take responsibility for medication-based rehabilitation]
   Tidsskr Nor Laegeforen, 127 (3), 296-7
   PubMed 17279108
7. Waal H, Krook AL, Hansteen V (2007)
   [Methadone treatment and heart arrhythmia]
   Tidsskr Nor Laegeforen, 127 (4), 459; author reply 459-60
   PubMed 17304281
8. Waal H, Krook AL, Hansteen V (2007)
   [Methadone and arrhythmia--final comment]
   Tidsskr Nor Laegeforen, 127 (7), 913; author reply 913
   PubMed 17435820

Publications 2006

1. Bramness JG (2006)
   [CYP genotyping in psychopharmacological treatment]
   Tidsskr Nor Laegeforen, 126 (4), 480; author reply 480
   PubMed 16477294
2. Høiseth G, Bramness JG, Christophersen AS, Mørland J (2006)
   Carisoprodol intoxications: a retrospective study of forensic autopsy material from 1992-2003
   Int J Legal Med, 121 (5), 403-9
   DOI 10.1007/s00414-006-0139-1, PubMed 17115170
3. Høiseth G, Løvåsdal Ø, Titze TK, Bramness JG, Bachs L (2006)
   [Psychiatric and cognitive long-term effects of ecstasy]
   Tidsskr Nor Laegeforen, 126 (5), 596-8
   PubMed 16505868
4. Khiabani HZ, Bramness JG, Bjørneboe A, Mørland J (2006)
   Relationship between THC concentration in blood and impairment in apprehended drivers
   Traffic Inj Prev, 7 (2), 111-6
   DOI 10.1080/15389580600550172, PubMed 16854704
5. Kornør H, Waal H, Ali RL (2006)
   Abstinence-orientated buprenorphine replacement therapy for young adults in out-patient counselling
   Drug Alcohol Rev, 25 (2), 123-30
   DOI 10.1080/09595230500537209, PubMed 16627301
6. Mellingsaeter TC, Bramness JG, Slørdal L (2006)
   [Are z-hypnotics better and safer sleeping pills than benzodiazepines?]
   Tidsskr Nor Laegeforen, 126 (22), 2954-6
   PubMed 17117195

Publications 2005

1. Gustavsen I, Mørland J, Bramness JG (2005)
   Impairment related to blood amphetamine and/or methamphetamine concentrations in suspected drugged drivers
   Accid Anal Prev, 38 (3), 490-5
   DOI 10.1016/j.aap.2005.11.005, PubMed 16343411
2. Kornør H, Waal H (2005)
   From opioid maintenance to abstinence: a literature review
   Drug Alcohol Rev, 24 (3), 267-74
   DOI 10.1080/09595230500170241, PubMed 16096130
3. Kunøe N, Lobmaier P (2005)
   Blame the counselling, not the implant. A response to Oliver, Horspool & Keen (2005)
   Addiction, 100 (7), 1027-8; author reply 1028-9
   DOI 10.1111/j.1360-0443.2005.01209.x, PubMed 15955020
4. Olsen V, Gustavsen I, Bramness JG, Hasvold I, Karinen R, Christophersen AS, Mørland J (2005)
   The concentrations, appearance and taste of nine sedating drugs dissolved in four different beverages
   Forensic Sci Int, 151 (2-3), 171-5
   DOI 10.1016/j.forsciint.2005.01.017, PubMed 15939149
5. Vermund H, Krajci P, Eide TJ, Winther F (2005)
   Histopathological grading of laryngectomy specimens
   APMIS, 113 (7-8), 473-88
   DOI 10.1111/j.1600-0463.2005.apm_24.x, PubMed 16086817

Publications 2004

1. Kornør H, Waal H (2004)
   [Methadone dose, treatment duration and heroin use in drug-assisted rehabilitation]
   Tidsskr Nor Laegeforen, 124 (3), 332-4
   PubMed 14963504
2. Krook AL, Waal H, Hansteen V (2004)
   [Routine ECG in methadone-assisted rehabilitation is wrong prioritization]
   Tidsskr Nor Laegeforen, 124 (22), 2940-1
   PubMed 15550974
3. Olsen L, Christophersen AS, Frogopsahl G, Waal H, Mørland J (2004)
   Plasma concentrations during naltrexone implant treatment of opiate-dependent patients
   Br J Clin Pharmacol, 58 (2), 219-22
   DOI 10.1111/j.1365-2125.2004.02122.x, PubMed 15255807
4. Vermund H, Krajci P, Eide TJ, Winther F (2004)
   Laryngectomy whole organ serial sections--histological parameters correlated with recurrence rate
   Acta Oncol, 43 (1), 98-107
   DOI 10.1080/02841860310020366, PubMed 15068327
5. Waal H, Kornor H (2004)
   Abstinence-oriented therapies for opiate addicts
   Curr. Opin. Psychiatr., 17 (3), 169-174
   DOI 10.1097/00001504-200405000-00004

Publications 2003

1. Bachs L, Waal H (2003)
   [Naltrexone in the treatment of addiction]
   Tidsskr Nor Laegeforen, 123 (12), 1665-7
   PubMed 12821984
2. Waal H (2003)
   [Tragedies in drunk cells]
   Tidsskr Nor Laegeforen, 123 (8), 1047
   PubMed 12760215

Publications 2002

1. Bramness JG, Bachs LC, Waal H (2002)
   [Buprenorphine as maintenance treatment in rehabilitation of heroin addicts]
   Tidsskr Nor Laegeforen, 122 (25), 2452-4
   PubMed 12448114
2. Krook AL, Brørs O, Dahlberg J, Grouff K, Magnus P, Røysamb E, Waal H (2002)
   A placebo-controlled study of high dose buprenorphine in opiate dependents waiting for medication-assisted rehabilitation in Oslo, Norway
   Addiction, 97 (5), 533-42
   DOI 10.1046/j.1360-0443.2002.00090.x, PubMed 12033654
3. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ et al. (2002)
   The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma
   N Engl J Med, 346 (25), 1937-47
   DOI 10.1056/NEJMoa012914, PubMed 12075054

Publications 2000

1. Walby FA, Borg P, Eikeseth PH, Neegaard E, Kjerpeseth K, Bruvik S, Waal H (2000)
   [Use of methadone in the treatment of psychotic patients with heroin dependence]
   Tidsskr Nor Laegeforen, 120 (2), 195-8
   PubMed 10851915
2. Wiatrowska B, Krajci P, Berner A (2000)
   [Pseudo-Meigs' syndrome]
   Tidsskr Nor Laegeforen, 120 (3), 364-6
   PubMed 10827530

Publications 1999

1. Blix O, Bruvik S, Waal H (1999)
   [The Oslo methadone project]
   Tidsskr Nor Laegeforen, 119 (2), 242-6
   PubMed 10081358
2. Johansen FE, Pekna M, Norderhaug IN, Haneberg B, Hietala MA, Krajci P, Betsholtz C, Brandtzaeg P (1999)
   Absence of epithelial immunoglobulin A transport, with increased mucosal leakiness, in polymeric immunoglobulin receptor/secretory component-deficient mice
   J Exp Med, 190 (7), 915-22
   DOI 10.1084/jem.190.7.915, PubMed 10510081
3. Nilsen EM, Johansen FE, Kvale D, Krajci P, Brandtzaeg P (1999)
   Different regulatory pathways employed in cytokine-enhanced expression of secretory component and epithelial HLA class I genes
   Eur J Immunol, 29 (1), 168-79
   DOI 10.1002/(SICI)1521-4141(199901)29:01<168::AID-IMMU168>3.0.CO;2-8, PubMed 9933098
4. Norderhaug IN, Johansen FE, Krajci P, Brandtzaeg P (1999)
   Domain deletions in the human polymeric Ig receptor disclose differences between its dimeric IgA and pentameric IgM interaction
   Eur J Immunol, 29 (10), 3401-9
   DOI 10.1002/(SICI)1521-4141(199910)29:10<3401::AID-IMMU3401>3.0.CO;2-G, PubMed 10540352
5. Waal H, Morland J (1999)
   Addiction as impeded rationality
   ADDICTION: ENTRIES AND EXITS, 120-147

Publications 1998

1. Johansen FE, Bosløven BA, Krajci P, Brandtzaeg P (1998)
   A composite DNA element in the promoter of the polymeric immunoglobulin receptor regulates its constitutive expression
   Eur J Immunol, 28 (4), 1161-71
   DOI 10.1002/(SICI)1521-4141(199804)28:04<1161::AID-IMMU1161>3.0.CO;2-S, PubMed 9565355
2. Waal H (1998)
   [Is methadone a solution?]
   Tidsskr Nor Laegeforen, 118 (20), 3104
   PubMed 9760849
3. Waal H (1998)
   [Is methadone effective?]
   Tidsskr Nor Laegeforen, 118 (23), 3673
   PubMed 9820017
4. Waal H (1998)
   [Dogmatism on methadone]
   Tidsskr Nor Laegeforen, 118 (25), 3996
   PubMed 9830350

Publications 1997

1. Winberg JO, Hammami-Hauasli N, Nilssen O, Anton-Lamprecht I, Naylor SL, Kerbacher K, Zimmermann M, Krajci P, Gedde-Dahl T, Bruckner-Tuderman L (1997)
   Modulation of disease severity of dystrophic epidermolysis bullosa by a splice site mutation in combination with a missense mutation in the COL7A1 gene
   Hum Mol Genet, 6 (7), 1125-35
   DOI 10.1093/hmg/6.7.1125, PubMed 9215684

Publications 1996

1. Bramness JG (1996)
   [Interruptions of physicians' work at hospitals]
   Tidsskr Nor Laegeforen, 116 (14), 1719
   PubMed 8658445
2. Bramness JG (1996)
   [Save us from idiocy]
   Tidsskr Nor Laegeforen, 116 (17), 2083
   PubMed 8779151

Publications 1995

1. Brandtzaeg P, Krajci P (1995)
   The enterocyte and immunoglobulin transport
   Dyn.Nutr.Res., 4, 1-17
2. Faerden A, Waal H, Rønnow S (1995)
   [Long-term psychiatric patients in a sector of Oslo]
   Tidsskr Nor Laegeforen, 115 (29), 3638-41
   PubMed 8539723
3. Kamei M, Iwase T, Krajci P, Brandtzaeg P, Moro I (1995)
   Antibody production to secretory component (SC) using recombinant SC fragment
   Adv Exp Med Biol, 371A, 633-5
   DOI 10.1007/978-1-4615-1941-6_133, PubMed 8526006
4. Kulseth MA, Krajci P, Myklebost O, Rogne S (1995)
   Cloning and characterization of two forms of bovine polymeric immunoglobulin receptor cDNA
   DNA Cell Biol, 14 (3), 251-6
   DOI 10.1089/dna.1995.14.251, PubMed 7880445
5. Moro I, Takahashi T, Iwase T, Asano M, Takenouchi N, Nishimura S, Kudo I, Krajci P, Brandtzaeg P, Moldoveanu Z (1995)
   Expression of SC, IL-6 and TGF-beta 1 in epithelial cell lines
   Adv Exp Med Biol, 371A, 175-82
   DOI 10.1007/978-1-4615-1941-6_36, PubMed 8525901
6. Nilsen EM, Lundin KE, Krajci P, Scott H, Sollid LM, Brandtzaeg P (1995)
   Gluten specific, HLA-DQ restricted T cells from coeliac mucosa produce cytokines with Th1 or Th0 profile dominated by interferon gamma
   Gut, 37 (6), 766-76
   DOI 10.1136/gut.37.6.766, PubMed 8537046
7. Norstein J, Krajci P, Bergan A, Geiran O (1995)
   Intestinal perforation after ingestion of a blister-wrapped tablet
   Lancet, 346 (8985), 1308
   DOI 10.1016/s0140-6736(95)91918-x, PubMed 7475762
8. Rønnow S, Waal H (1995)
   [Increasing number of involuntary emergency admissions to psychiatric institutions]
   Tidsskr Nor Laegeforen, 115 (19), 2376-80
   PubMed 7667852

Publications 1993

1. Ersland S, Kringlen E, Waal H, Thaulow JF (1993)
   [Lobotomy at the Gaustad hospital]
   Tidsskr Nor Laegeforen, 113 (17), 2092-5
   PubMed 8337667

Publications 1992

1. Bramness J (1992)
   [Why change medical education? The reason for changing medical education]
   Tidsskr Nor Laegeforen, 112 (2), 234-5
   PubMed 1566263
2. Bramness JG (1992)
   [Admission criteria for medical studies]
   Tidsskr Nor Laegeforen, 112 (18), 2390
   PubMed 1412249
3. Brandtzaeg P, Halstensen TS, Huitfeldt HS, Krajci P, Kvale D, Scott H, Thrane PS (1992)
   Epithelial expression of HLA, secretory component (poly-Ig receptor), and adhesion molecules in the human alimentary tract
   Ann N Y Acad Sci, 664, 157-79
   DOI 10.1111/j.1749-6632.1992.tb39758.x, PubMed 1456647
4. BRANDTZAEG P, HALSTENSEN TS, HUITFELDT HS, KRAJCI P, KVALE D, SCOTT H, THRANE PS (1992)
   EPITHELIAL EXPRESSION OF HLA, SECRETORY COMPONENT (POLY-IG RECEPTOR), AND ADHESION MOLECULES IN THE HUMAN ALIMENTARY-TRACT
   Ann.NY Acad.Sci., 664, 157-179
   DOI 10.1111/j.1749-6632.1992.tb39758.x
5. Kvale D, Krajci P, Brandtzaeg P (1992)
   Expression and regulation of adhesion molecules ICAM-1 (CD54) and LFA-3 (CD58) in human intestinal epithelial cell lines
   Scand J Immunol, 35 (6), 669-76
   DOI 10.1111/j.1365-3083.1992.tb02973.x, PubMed 1376489
6. Solberg R, Sistonen P, Träskelin AL, Bérubé D, Simard J, Krajci P, Jahnsen T, de la Chapelle A (1992)
   Mapping of the regulatory subunits RI beta and RII beta of cAMP-dependent protein kinase genes on human chromosome 7
   Genomics, 14 (1), 63-9
   DOI 10.1016/s0888-7543(05)80284-8, PubMed 1358799
7. Waal H (1992)
   [Methadone treatment of narcotic addicts--can it be defended?]
   Tidsskr Nor Laegeforen, 112 (3), 374-5
   PubMed 1553680

Publications 1990

1. Knutsen T, Waal H (1990)
   [Therapeutic and health care needs of HIV positive drug abusers. A study from an emergency institution]
   Tidsskr Nor Laegeforen, 110 (22), 2861-3
   PubMed 2219061

Publications 1989

1. Brandtzaeg P, Halstensen TS, Kett K, Krajci P, Kvale D, Rognum TO, Scott H, Sollid LM (1989)
   Immunobiology and immunopathology of human gut mucosa: humoral immunity and intraepithelial lymphocytes
   Gastroenterology, 97 (6), 1562-84
   DOI 10.1016/0016-5085(89)90406-x, PubMed 2684725
2. Helgeland I, Waal H (1989)
   [Can adolescents with behavioral disorders be helped? Problems among young people--behavioral disorders--preventive attempts--follow-up studies--evaluation]
   Tidsskr Nor Laegeforen, 109 (14), 1509-12
   PubMed 2749637
3. Waal H (1989)
   [Buprenorphine (Temgesic)--a new agent for abuse]
   Tidsskr Nor Laegeforen, 109 (12), 1326-7
   PubMed 2734763
4. Waal H, Helgeland I (1989)
   [Punishment, fostering, education and treatment. An integrated model for adolescents with behavioral disorders]
   Tidsskr Nor Laegeforen, 109 (14), 1513-6
   PubMed 2749638